
•Title: A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-
Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, 
Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects 
With Developmental and/or Epi[INVESTIGATOR_98576]: [REMOVED]
Protocol Approve Date: 21 March 2018
Certain information  within this protocol has been  redacted (ie, specific content is masked irreversibly from 
view with a black/blue bar) to protect either personally identifiable information ([COMPANY_003]) or company 
confidential information (CCI). 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of [COMPANY_005] or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
1.0 TITLE PAG
E
TAKEDA PHARMACEUTICALS
PROTOCOL
A Phase 1b/2a Mult icenter, Randomized, Double -Blind, Pl acebo -Controlled, Parallel -Group, 
Dose -Escal ation Study  With an Open -Label Part to Examine the Safety, Tolerabilit y, 
Pharmacokinet ics, and Pharmacodynamics of TAK -[ADDRESS_108454] ive Therapy in Subjects 
With Developmental and/or Epi[INVESTIGATOR_98577] -[ADDRESS_108455] ive Therapy in Subjects Wit h Devel opmental  and/or Epi[INVESTIGATOR_98578]: [COMPANY_005] Development Center Americas, Inc.
One [COMPANY_005] Parkway
Deerfield, IL [ZIP_CODE]
Study Number: TAK -935-2001
IND Number: [ADDRESS_108456] Number: Not applicable
Compound: TAK -935
Date: 21March 2018 Amendment Number: 03
Amendment History:
Date Amendment Number Region
[ADDRESS_108457] Type / Role Contact
[CONTACT_45300]
(medical advice on protocol and compound)
Responsible Medical Officer (carries overall 
responsibility for the conduct of the study)[COMPANY_003]
TAK -[ADDRESS_108458] for the individual part icipants in accordance 
with the requi rements of this clinical study  protocol and also in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declaration of He lsinki.
International Council for Harmonisat ion E6 Good Clinical Practice Conso lidated Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws, clinical 
trial discl osure l aws, and regul ations.
TAK -935 
Study No. TAK -935-2001 Page 4of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL1.3 Protocol Amendment 03 Summary of Changes
Rationale for Amendment 03
This document describes the changes in reference to the protocol incorporating Amendment 
No.03. The primary reason for this amendment i s to allow administration of TAK -935 or placebo 
via stable gastrostomy tub e (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube after 
finalizat ion of chemistry , manufacturing, and controls (CMC )in vitro studies demonstrating 100% 
drug delivery through a G -tube when crushed and suspended in water.
Minor grammat ical, editori al, and formatting changes are included for clarificat ion purposes only.
For specific descript ions of text changes and where the changes are located, see Appendix E.
Changes in Amendment 03:
1.Clarified that TAK -935 or placebo can be administered either orally or via stable G -tube/ PEG 
tube.
2.Clarified that a separate consent form will be obtained for subje cts wi th G-tube/PEG tubes.
3.Added inclusio n criteria related to subjects with G -tube/PEG tubes.
4.Modified exclusio n criteria to all ow the use of medi cal marijuana.
5.Modified secondary  endpoints to rem ove est imation of addit ional parameters.
6.Removed body  weight/body  mass index (BMI) from secondary and exploratory  endpo ints.
7.Modified study  drug dosing and regimen sect ions to cl arify how study  drug will be 
administered via G -tube/ PEG tube.
8.Modified study  drug dispensing procedures to clarify  how the invest igative product ( IP)will 
be prepared for administration via G -
tube/PEG tube.
9.Clarified when open -label extensio n study  is expected to be init iated.
10.Updated the medical mo nitor contact [CONTACT_4203].
TAK -[ADDRESS_108459] igator’s Brochure, and any 
other product information provided by [CONTACT_456]. I agree to conduct this study  in accordance 
with the requirements of this protocol and also to protect the rights, safet y, privacy, a nd well -being 
of study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable law s and regul ations, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the study  site agreement.
Responsibilit ies o f the Invest igator ( Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in
 Appendix Dof this proto col.
Signature [CONTACT_4235] (print)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provi nce)
Locati on of  Facilit y (Country )
TAK-[ADDRESS_108460] of Abbreviations ...............................................................................................17
3.4 Corporate Identification ...........................................................................................18
4.0 INTRODUCTI ON.........................................................................................................19
4.1 Background .............................................................................................................19
4.2 Rationale for the Proposed Study .............................................................................19
5.0 STUDY OBJECTIVES AND ENDPOINTS ..................................................................21
5.1 Objectives ................................................................................................................21
5.1.1 Prima ry Objective ..............................................................................................21
5.1.2 Secondary Ob jective ..........................................................................................21
5.1.3 Exploratory Objectives .......................................................................................21
5.2 Endpoints .................................................................................................................21
5.2.1 Prima ry Endpoint ...............................................................................................21
5.2.2 Secondary Endpoints ..........................................................................................21
5.2.3 Exploratory Endpoints .......................................................................................22
6.0 STUDY DESIGN AND DE SCRIPTION .......................................................................23
6.1 Study Design ...........................................................................................................236.2 Justification for Study De sign, Dose, and Endpoint s ................................................28
6.2.1 Study Desi gn......................................................................................................28
6.2.2 Dose ..................................................................................................................28
[IP_ADDRESS] Dose Selection Rationale .........................................................................28
[IP_ADDRESS] Dose Selection P rocedures .......................................................................29
6.2.3 Endpoints ...........................................................................................................30
[IP_ADDRESS] Safety Endpoints ......................................................................................30
[IP_ADDRESS] PK Endpoints ...........................................................................................30
[IP_ADDRESS] ................................................................................30
CCI
TAK -935 
Study No. TAK -935-2001 Page 7of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL6.2.3.4 Seizure Assessment by  [CONTACT_98620] ............................................. 30
6.3 Prem ature Terminat ion or Suspension o f Study  or Study  Site................................... 31
6.3.1 Criteria for Premature Terminat ion or Suspension of the Study .......................... 31
6.3.2 Criteria for Premature Terminat ion or Suspension of Study  Sites....................... 31
6.3.3 Procedures for Prem ature Termination or Suspension of the Study  or the 
Parti cipation of  Study  Sites................................................................................ 31
7.0 SELECTION AND DISCONTINUATION/WITH DRAWAL OF SUBJECTS .............. [ADDRESS_108461] ...................................... 37
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 38
8.1 Study  Drug and Materials ........................................................................................ 38
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling ..................................... 38
[IP_ADDRESS] Study  Drug .............................................................................................. 38
[IP_ADDRESS] Rescue Medicat ion.................................................................................. 38
[IP_ADDRESS] Sponsor -Supp lied Drug ............................................................................ 38
8.1.2 Storage ............................................................................................................... 38
8.1.3 Dose and Regimen ............................................................................................. 39
8.1.4 Overdose ............................................................................................................ 39
8.2 Study  Drug Assignment and Dispensing Procedures ................................................ 40
8.3 Randomization Code Creation and Storage .............................................................. 40
8.4 Unblinding Procedure .............................................................................................. 41
8.5 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 41
9.0 STUDY PLAN .............................................................................................................. 43
9.1 Study  Procedures ..................................................................................................... 43
9.1.1 Informed Consent Procedure .............................................................................. 43
[IP_ADDRESS] Study  Inform ed Consent Procedure .......................................................... 43
[IP_ADDRESS] PGx Informed Consent Procedure ............................................................ [ADDRESS_108462] ..............................................................................50
9.1.17 Collection of Blood Samp les for PGx Ev aluation ...............................................51
9.1.18 PK Sample Collection and Analysis ...................................................................52
[IP_ADDRESS] Collection of Plasma Samples for TAK-935 and M-I PK Evaluation .......52
[IP_ADDRESS] Bioanalytical Methods for TAK-935 and M-I ..........................................52
[IP_ADDRESS] PK Parameter s.........................................................................................53
9.1.19 PD Sample Collection and Analysis ...................................................................53
[IP_ADDRESS] Collection of Plasma Samples for PD Evaluation .....................................53
[IP_ADDRESS] .............................................................53
[IP_ADDRESS] PD Parameter s.........................................................................................53
9.1.20 Concomitant  AEDs Sample Co llection and Analysis ..........................................54
[IP_ADDRESS] Collection of Plasma Samples for Concomitant AED PK Evaluation .......54
[IP_ADDRESS] Analytical Methods for Concomitant AEDs .............................................[ADDRESS_108463] Treatment Comp liance ..............................................................55
9.3 Schedule of Observation s and Proce dures ................................................................55
9.3.1 Screening/Bas eline Peri od..................................................................................56
9.3.2 Randomization ...................................................................................................56
9.3.3 Part 1 .................................................................................................................56
9.3.4 Part 2 .................................................................................................................56
9.3.5 Final Visi t ..........................................................................................................57
9.3.6 Follow-up P hone Call ........................................................................................57
9.3.7 Follow-up Vi sit ..................................................................................................57
9.3.8 Poststudy Care ...................................................................................................58CCI
TAK -935 
Study No. TAK -935-2001 Page 9of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL9.4 Biological Sample Retent ion and Destruction .......................................................... 58
10.0 ADVERSE EVENTS .................................................................................................... 59
10.1 Definit ions............................................................................................................... 59
10.1.1 AEs.................................................................................................................... 59
10.1.2 Addit ional Po ints to Consider for AEs ................................................................ 59
10.1.3 SAEs .................................................................................................................. 61
10.1.4 Intensit y of AEs.................................................................................................62
10.1.5Causalit y of AEs................................................................................................ 62
10.1.6 Relationship to Study  Procedures ....................................................................... 62
10.1.7 Start Date ........................................................................................................... 63
10.1.8 Stop Date ........................................................................................................... 63
10.1.9 Frequ ency .......................................................................................................... 63
10.1.10 Action Concerning Study  Drug .................................................................... 63
10.1.11 Outcom e....................................................................................................... 63
10.2 Procedures ............................................................................................................... 64
10.2.1 Colle ction and Reporti ng of AEs........................................................................ 64
[IP_ADDRESS] AE Collection Period ............................................................................... 64
[IP_ADDRESS] AE Reporting ........................................................................................... [ADDRESS_108464] ics........................... 70
13.1.3 Safety Analysis .................................................................................................. 71
[IP_ADDRESS] AEs ......................................................................................................... 71
[IP_ADDRESS] Other Safet y Endpo ints............................................................................ [ADDRESS_108465] igator Consent to Use of Personal Informat ion.......................................... 89
Appendix E Detailed Descript ion of Amend ments to Text ..................................................... 90
TAK-935 
Study No. TAK-935- 2001 Page 12 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL2.0 STUDY SUMMARY
Name [CONTACT_790]:
[COMPANY_005] Development Center Americas, Inc.
One [COMPANY_005] ParkwayDeerfield, IL 60015Compound:
TAK-935
Title of Protocol: A Multicenter, Randomized, 
Double-Blind, Placebo-Cont rolled, Par allel-Group, 
Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epi[INVESTIGATOR_98579].: [ADDRESS_108466] No.:
Not applicable.
Study Number: TAK-935-2001 Phase: 1b/2a
Study Design:
Adult subjects (aged ≥18 and ≤65 years) with a diagnosis of developmental and/or epi[INVESTIGATOR_98580] (ie, drop seizures, tonic-clonic, tonic, bilateral clonic, atonic, 
myoclonic-atonic, myoclonic-tonic-clonic, focal seizures with bilateral hyperkinetic motor features) (average of ≥[ADDRESS_108467] 3 months) based on the investigator’s assessment will be enrolled. Drop seizures are defined as a seizure involving the entire body, trunk or head that leads to a fall, injury, slumpi[INVESTIGATOR_10714] a chair, or head hitting the surface, or could have led to a fall or injury, depending on the position of the subject at the time of the attack or spell. Drop seizures will be captured separately (eg, tonic seizures leading to a drop will be captured as a drop).
The study will screen a sufficient number of subjects to ensure approximately 20 randomized subjects.
At the Screening Visit (Visit 1), informed consent and/or assent (if applicable) is obtained from the subjects and/or 
subjects’ legally acceptable representative. Subjects will then undergo screening procedures to assess study eligibility in accordance with the study entry criteria. At this Screening Visit and at subsequent visits, subjects and/or subjects’ caregivers will be provided with a seizure diary and will be instructed to record seizure data on a daily basis starting at 
Baseline and throughout the study.  
 
. The 4-week Baseline Period 
 can begin as soon as informed consent is signed. At the end of the 4-week Baseline Period and 
after confirmation of eligibility, subjects will return to the clinic on Day 1 in Part 1 (Visit 2) for randomization. If a subject does not meet the eligibility criteria during the Screening/Baseline Period, the subject will be discontinued from the study (screen failure).
The study will consist of 2 parts:
Part 1 is a randomized double-blind part consisting of 3 periods: a screening/baseline period (4-6 weeks), titration 
period (20 days), and maintenance period (10 days). The target final dose of 300 mg twice daily (BID) will be reached after a 20-day titration period.
Part 2 is an open-label continuation part consisting of 4 periods: a titration period (10 days), maintenance period 
(44 days), de-escalation period (3-6 days) and follow-up period (30 days).
Part 1 of the study is designed to investigate the safety, tolerability, pharmacokinetics (PK), and PD in adult subjects 
with developmental and/or epi[INVESTIGATOR_98581] a double-blind manner.  
 exploratory manner.
Approximately 20 adult subjects who demonstrate ≥1 bilateral motor seizure during the 4-week Baseline Period will 
be randomly assigned on Day 1 (Visit 2) to receive TAK-935 (n=16) or matching placebo (n=4 BID orally or via 
gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube for [ADDRESS_108468] (IP) (TAK-935 or placebo) at 100 mg BID from Days 
1 through 10. Subjects who cannot tolerate the 100 mg BID dosi ng will be withdrawn from the study. On Day 11 (Visit 
CCICCICCI
CCI
TAK-935 
Study No. TAK-935- 2001 Page 13 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL3), subjects will return to the clinic and the IP dose will be increased to 200 mg BID; this dose level will be maintained 
from Days 11 through 20 but may be reduced to 100 mg BID in subjects who cannot tolerate the 200 mg BID dose or demonstrate safety concerns, based on the investigator’s judgment and in consultation with the subject’s caregiver, when applicable. On Day 21 (Visit 4), subjects will return to the clinic; at this visit, the investigator will review the subject’s safety and will discuss the benefit-risk with the subject or the subject’s legally acceptable representative before increasing the dose from 200 mg BID to 300 mg BID, and this dose level will be maintained from Days 21 through 30. The dose may be reduced to 200 mg BID in subjects who cannot tolerate the 300 mg BID dose or demonstrate safety concerns, as described above. Subjects for whom the dose was reduced to a lower dose level will stay on that dose level until the end of Double-Blind Treatment Period. Three days after each dose up-titration or 
de-escalation, subjects will be contact[CONTACT_98621], c oncomitant medication use, and 
adverse events (AEs). Any change in dose will be documented in the subject’s clinic chart and the subject’s caregiver will be advised to note the same in the dosing card.
Part 2 of the study is designed to investigate the safety, tolerability, PK, and PD of TAK-935 in adult subjects with 
developmental and/or epi[INVESTIGATOR_98582]-label manner. Efficacy of TAK-[ADDRESS_108469] the option to continue directly into the Open-Label Treatment Period in Part 2. Because some subjects may 
enter Part 2 after receiving placebo and others on TAK-935 up to 300 mg BID, to maintain the study blind, all subjects will start on TAK-935 200 mg BID at the start of Part 2. On  Day 31 (Visit 5), subjects will return to the clinic and 
receive TAK-935 200 mg BID from Days 31 to 40 but may be reduced to 100 mg BID in subjects who cannot tolerate the 200 mg BID dose or demonstrate safety concerns, based on the investigator’s judgment and in consultation with the subject’s caregiver, when applicable. Subjects who cannot tolerate the 100 mg BID dose or demonstrate safety concerns, based on the investigator’s judgment and in consultation with the subject’s caregiver, will be discontinued from the study. On Day 41 (Visit 6), subjects will return to the clinic; at this visit, the investigator will review the subject’s safety and will discuss the benefit-risk with the subject or the subject’s legally acceptable representative before increasing the dose from 200 mg BID to 300 mg BID, and this dose level will be maintained until the Final Visit (Visit 7) for the dose de-escalation phase. Subjects’ dose may be increased or decreased before Day 41 (Visit 6) based on clinical condition (ie, increasing seizures) and investigator judgment. This dose may be reduced to 200 mg 
BID in subjects who cannot tolerate the 300 mg BID dose or demonstrate safety concerns, as described above. 
Subjects for whom the dose was reduced to a lower dose level will stay on that dose level until the Final Visit (Visit 7) for the dose de-escalation phase. Three days after each dose up-titration or de-escalation, subjects will be contact[CONTACT_98622], concomitant medication use, and AEs. Any change in dose will be documented in the subject’s clinic chart and the subject’s careg iver will be advised to note the same in the dosing card.
On Day 85 (Visit 7), subjects will return to the clinic for the Final Visit and enter the 3- or 6-day de-escalation phase. 
Immediately after the last dose is the 30-day Follow-up Period comprised of a Follow-up Phone Call (Visit 8) on Day 91 and a Follow-up Visit (Visit 9) on Day 121. At the Follow-up Visit, subjects will return to the clinic for study procedures including PD and antiepi[INVESTIGATOR_32551] (AED) blood sample collection.
Any subject who prematurely withdraws from the study should proceed directly to the Final Visit (at time of 
withdrawal), including dose de-escalation, as appropriate, followed by [CONTACT_941] 30-day Follow-up Period.CCI
TAK -935 
Study No. TAK -935-2001 Page 14of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALStudy Schem atic:
Primary Objective:
To characterize the multiple -dose safety and tolerability profile of TAK -935 in adult subjects with developmental 
and/o r epi[INVESTIGATOR_25280] .
Secondary Objective:
To characterize the multiple -dose PK profile of TAK -935 in adult subjects with developmental and/or epi[INVESTIGATOR_98583].
Subject Population: Adult subjects aged ≥18 and ≤65 years with developmental and/or epi[INVESTIGATOR_98584] o n background AED therapy and continued seizure activity .
Number of Subjects:
Approximately 20 subjects (n=16 for TAK -935 and n=4 
for placebo) for Part 1.
Up to 20 subjects (all TAK -935) for Part 2. Number of Sites: 
~11 sites in North America
Dose Levels:
TAK -935 100, 200, and 300 mg BID.
Matching placebo BID.Route of Administration:
Oral or via G -tube/PEG -tube
Duration of Treatment:
Part 1: 30 days
Part 2: ~60 daysPeriod of Evaluation:
~20 weeks (includes 4 to 6-week Screening/Baseline 
and 30-day Follow -up Periods)
Main Criteria for Inclusion:
The subject is a male or female aged ≥18 and ≤[ADDRESS_108470] dose of study 
drug.
The subject has a documented clinical diagnosis of developmental and/or epi[INVESTIGATOR_98585], defin ed as an average of ≥[ADDRESS_108471] 3 months, based on the 
investigator’s assessment, and a monthly average of ≥[ADDRESS_108472].
The subject is taking 1 to 4 AEDs at a stable dose for ≥4 weeks before Screening (Visit 1), and the subject or 
subject’s legally acceptable representative is willing to keep the regimen(s) stable throughout the study.
The subject has an average of ≥1 bilateral motor seizure per month during the 4 -week Baseline Period (ie, drop 
seizures, to nic-clonic, tonic, bilateral clonic, atonic, myoclonic -atonic, myoclonic -tonic -clonic, focal seizures 
with bilateral hyperkinetic motor features). If the subject has <[ADDRESS_108473] will be considered a screen failure.

TAK -935 
Study No. TAK -935-2001 Page 15of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALMain Criteria for Exclusion:
The subject was admitted to a medical facility for treatment of status epi[INVESTIGATOR_98586] 3 months before Screening (Visit 1).
The sub ject had a vagal nerve stimulator implanted within 6 months before Screening (Visit 1) and settings have 
been changed within 1 month of the Screening Visit (Visit 1) and/or are anticipated to change during the study.
The subject has unstable, clinically si gnificant neurologic (other than the disease being studied), psychiatric, 
cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, hematopoietic, or 
endocrine disease or other abnormality, which may impact the ability of the subject to participate or potentially 
confound the study results. It is the responsibility of the investigator to assess the clinical significance; however, 
consultation with the Medical Monitor may be warranted.
The subject has a history of suicida l behavior or any suicidal ideation of type 4 or 5 on the Columbia -Suicide 
Severity  Rating Scale (C -SSRS) at Screening (Visit 1). If the subject is unable to comply with the C -SSRS due to 
developmental status, a parent proxy may be used for the completion of the C -SSRS. The Investigator may also 
use clinical judgment, which must then be documented in the source document.
Main Criteria for Evaluation and Analyses:
Primary Endpoint
Percentage of subjects with at least 1 treatment -emergent adverse event (TEAE ), as reported by [CONTACT_98623]’ caregivers or observed by [CONTACT_093], after TAK -935 treatment.
Secondary Endpoints
Population mean estimates of drug clearance (CL), volume of distribution of the central compartment (V c), 
absorption rate constant (K a), volume of distribution of the peripheral compartment (V p), intercompartmental 
clearance (Q), the maximum plasma concentration (C max), the area under the plasma concentration -time curve 
over a dosing interval (AUC 0-tau), the average concentra tion during a dosing interval at steady -state (C av,ss), and 
the plasma concentration immediately prior to dosing (C trough ) for TAK -935.
Percentage of subjects with at least 1 markedly abnormal value for clinical laboratory evaluations, vital signs, and 
electrocardiogram (ECG) parameters after TAK -935 treatment.
Statistical Considerations:
TEAEs will be a primary endpoint for each part of the study. TEAEs will be summarized using descriptive statistics 
(number and percentage of subjects) for the safety analysis set. No statistical testing will be performed or inferential 
statistics will be generated.
The PK of TAK -[ADDRESS_108474], vital sign, weight/BMI, and ECG parameter 
values that meet [COMPANY_005]’s predefined criteria for markedly abnormal values at least once postdose will be summarized 
by [CONTACT_98624]. Plasma concentrations of TAK -[ADDRESS_108475] and summarized 
by [CONTACT_98625]. A population PK/PD analysis approach will be used to 
determine the population estimates for TAK -935.
After all subjects have completed the Double -Blind Trea tment Period or have discontinued from the study (and prior 
to completion of the Open -Label Period), an unblinded safety summary may be generated (Section 13.2). 
Sample Size Justification: Approximately 20 adult subjects are planned to be randomized. A formal sample size 
calculation was not performed for this study. The current sample size is deemed appropriate to evaluate the safety and 
tolerabili ty of TAK-935 before dosing in pediatric epi[INVESTIGATOR_24590] <[ADDRESS_108476] aspartate aminotransferase
BA bioavailability
BID twice daily
BMI body mass index
Cav,ss average concentration during a dosing interval at steady -state
CFR Code of Federal Regulations
CH24H 24S-hydroxy lase
CNS central nervous system
C-SSRS Columbia -Suicide Severity Rating Scale
ECG electrocardiogram
eCRF electronic case report form
EEG electroencephalogram
EO enzyme occupancy
FAS full analy sis set
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT -glutamy l transferase
G-tube gastrostomy tube
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HCV hepatitis C virus
HIV human immunodeficiency virus
ICF informed consent form
ICH International Council for Harmonisation
ID identification
IEC Independent Ethics Committee
ILAE International League Against Epi[INVESTIGATOR_98587] -[ADDRESS_108477] multiple -rising dose
PD pharmacodynamic(s)
PDR posterior dominant rhythm
PEG percutaneous endoscopic gastrostomy
PET positron emission tomography
PGx pharmacogenomic(s)
PK pharmacokinetic(s)
PPS per-protocol set
PTZ penty lenetetrazol
QD once daily
SAE serious adverse event
SAP statistical analysis plan
SRD single -rising dose
S[LOCATION_003]R suspected unexpected serious adverse reaction
TEAE treatment -emergent adverse event
ULN upper limit of normal
3.4 Corporate Identification
TDC Japan [COMPANY_005] Development Center Japan
TDC Asia [COMPANY_005] Development Center Asia ,Pte Ltd
TDC Europe [COMPANY_005] Development Centre Europe Ltd.
TDC Americas [COMPANY_005] Development Center Americas, Inc.
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
[COMPANY_005] TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
TAK -[ADDRESS_108478] ive cho lesterol 24S -hydroxylase (CH24H) inhibitor currently in 
development for adjunct treatment for epi[INVESTIGATOR_98588].
In the brain, cholesterol is metabo lized by [CONTACT_25292]24H, which is specifically and const itutively  
expressed in neurons, to 24S -hydroxycho lesterol (24HC). Thi s cho lesterol metabo lite, 24HC, 
leaves the brain via lipoproteins and is excreted in bile. Aberrant cholesterol metabo lism is 
implicated in epi[INVESTIGATOR_98589]/syndromes.
Under normal condit ions, extracellular glutamate is sequestered by  [CONTACT_98626]. Upon central nervou s system  (CNS) injury , CH24H 
is induced in react ive astrocytes and microglia. This leads to disruption in astrocy tic gl utam ate 
homeostasis and a large increase in extracellular glutamate levels. As the CH24H enzyme converts 
cholesterol  essent ial for the in tegrity of plasma membrane lipid rafts to 24HC, the circulat ing 
levels o f 24HC increase and may further contribute to underlying pathophysio logical  processes. 
Excessive extracellular glutamate and 24HC levels are thought to play  major rol es in 
excitotoxici ty either through a sustained act ivation of the N -methyl-D- aspartate (NMDA) receptor 
channel or as a posit ive allosteric modulator of the receptor [1]. The processes may be equally 
important in contribut ing to the enhanced glutamatergic act ivity observed i n epi[INVESTIGATOR_98590].
To date, TAK- 935 has been studied in 4 clinical studies including a single -rising dose (SRD) 
first-in-human study  (TAK -935- 101), a single -dose posi tron emissio n tom ography  (PET) target 
occupancy  study  (TAK -935- 1003), a m ultiple-rising dose (MRD) study  (TAK -935- 1002), and a 
single- dose rel ative bioavailabilit y (BA) and food -effect study  (TAK -935- 1005). The 
pharmacokinet ics (PK) and pharmacodynamics (PD) of TAK -935 administered as an oral so lution 
or tabl et in healt hy subjects were chara cterized in these studi es. In addit ion, the PET study  
provi ded clinical evidence o f dose-dependent decreases in plasma 24HC concentrations and PET 
occupancy  measurements that were dose -and time -dependent and correlated with circulat ing 
levels o f 24HC.
Forfurther information, refer to the TAK -935 Investi gator’s Brochure.
4.[ADDRESS_108479] ivity itself may contribute to severe c ognitive and behavioral impairments 
above and bey ond what might be expected from the underlying patho logy alone (eg, corti cal 
malform ation) and that can worsen over time [2]. These disorders are generally diagnosed in 
childhood and adolescence, varying in their eti ologies, sei zure ty pes, el ectroencephalographic 
patterns, cognit ive defic its, and prognosi s, while sharing a consistent and significant impact on 
neuro logical devel opment.
TAK -[ADDRESS_108480] Epi[INVESTIGATOR_002]  (ILAE) recent ly expanded this def inition to i nclude 
disorders that m ay resul t in developmental delay  before epi[INVESTIGATOR_98591]/or Epi[INVESTIGATOR_98592] [3].
The current study  is desi gned to f urther characterize the safet y, tolerabilit y, PK, and PD of 
multiple-dose TAK -935 administration in adult subjects with developmental and/or epi[INVESTIGATOR_98593]. An addit ional aim is to explore the effects of TAK -935 on seizure frequency  
using a seizure diary . In addi tion, this study  will use a dose -escalat ion design, which will help 
guide dosing recommendations for future studies.
Pharmacogeno mic (PGx) analysis may be conducted to investigate the contribut ion of genet ic 
variance on drug response, for example, its efficacy and safet y. As PGx is an evo lving science, 
currently many genes and their funct ions are not yet fully  understood. Future data may  suggest a 
role of som e of these genes in drug response and safet y that may lead to addi tional 
hypothesis -generating explorato ry research on stored samples. Participat ion of study  subjects in 
PGx sample co llection is optional.
TAK-935 
Study No. TAK-935- 2001 Page 21 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objective
!To characterize the multiple-dose safety and to lerability profile of TAK-935 in adult subjects 
with developmental and/or epi[INVESTIGATOR_25280] .
5.1.2 Secondary Objective
!To characterize the multiple-dose PK profile of TAK-935 in adult subjects with developmental 
and/or epi[INVESTIGATOR_98594] (AEDs).
5.1.3 Explor atory Objectives
5.2 Endpoints
5.2.1 Primary Endpoint
!Percentage of subjects with at least 1 treatment-emergent adverse event (TEAE), as reported 
by [CONTACT_98627]’ caregivers or observed by [CONTACT_093], after TAK-935 
treatment .
5.2.2 Secondary Endpoints
!Population mean es timates of drug clearance (CL), volume of distribution of the central 
compartment (V c), absorption rate constant (K a), volume of distribution of the peripheral 
compartment (V p), intercompartmental clearance (Q), the maximum plasma concentration 
(Cmax), the area under the plasma concentration-time curve over a dosing interval (AUC 0-tau), 
the average concentration during a dosing interval at steady-state (C av,ss), and the plasma 
concentration immediately prior to dosing (C trough) for TAK-935.
!Percentage of subjects with at least 1 markedly abnormal value for clinical laboratory 
evaluations, vital signs, and electrocardiogram (ECG) parameters after TAK-935 treatment.CCI
TAK-935 
Study No. TAK-935- 2001 Page 22 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL5.2.3 Exploratory Endpoints
CCI
TAK-935 
Study No. TAK-935- 2001 Page 23 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL6.0 STUDY DESIGN AND DESCRIPTION
6.1 Study Design
This phase 1b/2a, multicenter, randomized, double-blind, placebo-c ontrolled, parallel-group, 
dose-escalation study with an open-label part is designed to examine the safety, tolerability, PK, 
and PD of TAK-935 as adjunctive therapy in adult subjects with a diagnosis of developmental 
and/or epi[INVESTIGATOR_25280]. This study w ill be conducted at approximately 11 sites in North 
America with experience in conducting clinical studies in patients with rare epi[INVESTIGATOR_31629].
Adult subjects (aged ≥18 and ≤65 years) with a diagnosis of developmental and/or epi[INVESTIGATOR_98595] (ie, drop seizures, tonic-clonic, tonic, 
bilateral clonic, atonic, myoclonic-atonic, myocl onic-tonic-clonic, focal seizures with bilateral 
hyperkinetic motor features) (average of ≥[ADDRESS_108481] 3 months) based on the 
investigator’s assessment will be enrolled. The study will screen a sufficient number of subjects to 
ensure approximately 20 randomized subjects.
At the Screening Visit (Visit 1), informed consent and/or assent (if applicable) is obtained from the 
subjects and/or subjects’ legally acceptable representative. Subjects will then undergo screening 
procedures to assess study eligibility in accordance with the study entry criteria (see  Appendix A
and Sections 7.1and 7.2).  
 
 
 
The 4-week Baseline Period  can begin as soon as 
informed consent has been signed. At the end of the 4-week Bas eline Period and after confirmation 
of eligibility, subjects will return to the clinic on Day 1 in Part 1 (Visit 2) for randomization. If a 
subject does not meet the eligibility criteria during the Screening/Baseline Period, the subject will 
be discontinued from the study (screen failure).
The study will consist of 2 parts:
!Part 1 is a randomized double-blind part consis ting of 3 periods: a screening/baseline period 
(4-6 weeks), titration period (20 days), and maintenance period (10 days). The target final dose 
of 300 mg BID will be reached after a 20-day titration period.
!Part 2 is an open-label continuation part consisting of 4 periods: a titration period (10 days), 
maintenance period (44 days), de-escalation period (3-6 days) and follow-up period (30 days).
Part 1 of the study is designed to investigate th e safety, tolerability, PK, and PD in adult subjects 
with developmental and/or epi[INVESTIGATOR_98581] a double-blind manner. Efficacy  
  
 
during the 4-week Baseline Period will be randomly assigned on C
CI CCICCICCI
CCI
TAK -935 
Study No. TAK -935-2001 Page 24of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALDay 1 (Visit 2) to receive TAK -935 (n=16) or matching placebo (n=4) twice daily (BID) orally or 
via stable gastrostomy tube (G -tube)/ percutaneous endoscopic gastrostomy (PEG) tube for 30
days during the Double -Blind Treatm ent Peri od. Subjects will init iate IP (invest igational product; 
TAK-[ADDRESS_108482] acebo) at 100 mg BID fro m Days 1 through 10. Subjects who cannot tolerate the 
100 m g BID dosing will be withdrawn from the study. On Day 11 (Visit 3), subjects will return to 
the clinic and the IP dose will be increased to 200 mg BID; this dose level will be maintained fro m 
Days [ADDRESS_108483] igator’s judgment and in consultatio n 
with the subject’s caregiver, whe n applicable. On Day  21 (Vi sit 4), subjects will  return to the 
clinic; at this visit, the invest igator will review the subject’s safet y data and will discuss the 
benefit -risk wi th the subject or subject’s legally acceptable representative before proceeding to 
increase the dose from [ADDRESS_108484]’s clinic chart and the subject’s caregiver will be 
advised to note the same in the dosing card.
On Day  1 (Visi t 2), PK, PD, AED, and optional PGx blo od sam ples will be collected before the 
morning dose of study  drug. PK and PD blood samples also will be collected at 1, 3, and 5 hours 
after the m orning dose on Day 1. On Day  11 (Visi t 3) and Day  21 (Visit 4), PK and PD blood 
samples (before and approxima tely 1 hour after morning dose), an AED blood sample (before 
morning dose), and seizure diary  data will  be collected.
Subjects who are unwilling to continue into Part [ADDRESS_108485] ly to the Final 
Visit (at Day 31), including dose de -escalat ion, as appropriate, followed by [CONTACT_941] [ADDRESS_108486] igate the safet y, tolerabilit y, PK, and PD of TAK -935 in 
adult subjects wi th devel opmental  and/or epi[INVESTIGATOR_98582] -label manner . All 
subjects who complete the Double -Blind Treatment Period in Part [ADDRESS_108487] the option to 
continue directly into the Open- Label  Treatm ent Peri od in Part 2. Because some subjects may 
enter Part 2 after receiving placebo and others TAK -935 up to 300 m gBID and to m aintain the 
study blind, all  subjects will start on TAK -935 200 mg BID at the start of Part 2. On Day  31 
(Visit 5), subjects will return to the clinic and receive TAK- [ADDRESS_108488] igator’s judgment and in consultat ion with the 
subject’s caregiver, when applicable. Subjects who cannot tolerate the [ADDRESS_108489] igator’s judgment and in consultat ion with the 
subject’s caregiver, will be discontinued from the study . On Day 41 (Visi t 6), subj ects will return 
to the clinic; at this visit, the invest igator will review the subject’s safet y data a nd will discuss the 
benefit -risk wi th the subject or subject’s legally acceptable representative before proceeding to 
TAK -935 
Study No. TAK -935-2001 Page 25of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALincrease the dose from 200 mg BID to 300 mg BID, and this dose level will be maintained unt il the 
Final Visit (Visit 7) for the dose de -escalation phase. Subjects’ dose may be increased or decreased 
before Day  41 (Visi t 6) based on clinical condit ion (ie, increasing seizures) and investigator 
judgment. This dose may be reduced to 200 mg BID in subjects who cannot tolerate the 300 mg 
BID dose or dem onstrate safet y concerns, as described above. Subjects for whom the dose was 
reduced to a lower dose level will stay on that dose level unt il the Final Visit (Visit 7) for the dose 
de-escalat ion phase. Three days after each dose up- titration or de -escalat ion, subjects will be 
contact[CONTACT_98628], concomitant medicat ion use, and AEs. Any 
change in dose will be documented in the subject’s clinic chart and the subject’s caregiver will be 
advised to note the same in the do sing card.
On Day  31 (Visi t 5), PK, PD, AED, and PGx (if collected on Day 1) blood sam ples will  be 
collected before the morning dose o f study drug and seizure data will also be co llected. On Day 41 
(Visit 6), PK, PD, and AED blood samples will be collected before the morning dose of study drug 
and seizure data will also be co llected.
On Day  85 (Visi t 7), subj ects will return to the clinic for the Final Visit and enter the 3 -or 6-day 
de-escalat ion phase. At this visit, PK, PD, and AED blood samples will be collected before the 
morning dose of study  drug and seizure data will also be co llected. Subjects will then enter the 
dose de -escalat ion phase and will be instructed to follow the applicable de -escalat ion dosing 
schedule outlined below:
For subjects on 300 mg BID during the maintenance phase, the dose will be de -escalated to 
200mg BID for 3 day s (Days 85-87) and subsequent ly to 100 mg BID for 3 day s 
(Day s 88-90).
For subjects on 200 mg BID during the maintenance phase, the dose will be de -escalated to 
100 mg BID for 3 days (Days 85-87).
For subjects on [ADDRESS_108490] dose is the 30 -day Follow-up Peri od com prised of a Foll ow-up Phone 
Call (V isit 8) on Day 91 and a Fo llow-up Visi t (Visi t 9) on Day 121. At the Follow -up Vi sit, 
subjects will return to the clinic for study  procedures including PD and AED blood sample 
collect ion.
In Parts [ADDRESS_108491] ion of the PK sample(s).
TAK -[ADDRESS_108492] and/or subjects’ caregiver 
throughout the Screening/Baseline Period up until the Follow -up Visi t (Vi sit 9) on Day  [ADDRESS_108493] who prematurely  withdraws from  the study  shoul d proceed di rectly to the Final Visit 
(at time of withdrawal ), including dose de -escalation, as appropriate, followed by [CONTACT_941] 30 -day 
Follow-up Peri od.
A schemat ic of the study design is shown in Figure 6.a. A schedule o f study procedures is listed in 
Appendix A.
TAK -935 
Study No. TAK -935-2001 Page 27of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALFigure 6.a Schematic of Study Design
Note 1: Circled numbers denote study visits.
Note 2: Subjects will remain on stable background AED therapy throughout the study.
Note 3: Starting doses for Parts 1 and 2 are shown; individual subject doses may be reduced to the previous dose level if there are safety and tolerability concerns at 
new dose level.
Note 4: Maintenance dose levels (ie, 100, 200, or 300 mg BID) will be de -escalated at the end of the maintenance phas e of Part 2, depending on the dose subjects are 
taking at that time (ie, if at TAK -935 300 mg BID level, reduce to 200 mg BID for 3 days followed by 100 mg BID for 3 days; if at the 200 mg BID level, reduce to 
100mg BID for 3 days; if at the 100 mg BID le vel, there is no de -escalation).

TAK-935 
Study No. TAK-935- 2001 Page 28 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL6.2 Justification for Study Design, Dose, and Endpoints
6.2.1 Study Design
This is a multicenter, randomized, double- blind, placebo-cont rolled, pa rallel -group, 
dose-escalation study with an open-label part to  examine the safety, tolerability, PK and PD, and 
preliminary efficacy of TAK-935 as adjunctive therapy in the treatment of subjects with a 
diagnosis of developmental and/or epi[INVESTIGATOR_98596] (ie, drop seizures, tonic-clonic, tonic,  bilateral clonic, atonic, myoclonic-atonic, 
myoclonic-tonic-clonic, focal seizures with b ilateral hyperkinetic motor features) (average of ≥[ADDRESS_108494] 3 months) based on the investigator’s assessment.
The safety, tolerability, PK, a nd  of TAK-935 after multiple-dose 
administration either orally or via G-Tube/PEG tube is first assessed (in Part 1), and then the 
longer-term safety, tolerability, and PK/PD of TAK-935 is assessed (in Part 2), with a seamless 
transition between Parts 1 and 2. The main goal of this study is to identify the safe and tolerable 
dose of TAK-935 to assess the efficacy of TAK-935 in subjects with developmental and/or 
epi[INVESTIGATOR_25280].
6.2.2 Dose
[IP_ADDRESS] Dose Selection Rationale
In the current study, dose selection was mainly based on the safety and tolerability d ata from the 
single- and multiple-dose phase 1 studies in healthy subjects administered TAK-935 as an oral 
solution. The selection of BID doses was also supported by [CONTACT_36532]/PD/enzyme occupancy (EO) 
modeling and simulations using available phase 1 data. In addition, nonclinical data from rodent 
epi[INVESTIGATOR_98597].
The safety results from the phase 1 studies show that TAK 935 (up to a single dose of 1350 mg) is 
generally safe and well tolerated in healthy male and female subjects. TAK-935 has been 
evaluated at doses up to 600 mg once daily (QD) as well as [ADDRESS_108495] study. Multiple rising doses of TAK-935 up to 400 mg QD for 14 days without 
up-titration was generally safe and well tolerated  in healthy subjects. When administered in a 
nontitrating fashion, AEs considered by [CONTACT_98629] 300 mg BID (mental confusion of mild intensity) and 600 mg QD (acute psychosis of 
severe intensity) dose levels. This TAK-935-2001 study will continue to investigate safety, 
tolerability, PK, and PD of TAK- 935 by [CONTACT_10338] a dose range of 100 mg  BID to 300 mg BID in an 
epi[INVESTIGATOR_98598]. In this study, a titr ation scheme will be used to ensure safety and 
tolerability before moving to higher doses.
In pentylenetetrazol (PTZ)-induced kindling in mice, TAK-935 at a dose of 1 mg/kg resulted in a 
statist ically signif icant reduction in seizure counts. This dose also resulted in an approximately 
60% reduction in mean brain 24HC levels, which translated to an average EO of approximately CCI
TAK -935 
Study No. TAK -935-2001 Page 29of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL65%. At higher doses, TAK -935 exerted stronger effects on generalized seizures. The 1 mg/kg 
dose was determined to be the minimum effect ive dose of TAK -935.
A select ive PET ligand was developed and used to assess the CNS target engagement of TAK -935 
in healt hy adult subjects, and a preliminary PK/PD/EO model was developed. First ly, an empi[INVESTIGATOR_98599] l 
PK model was developed to characterize complex and nonlinear PK data in healt hy adult subjects 
from the SRD and MRD studies as well as the relative BA study comparing the exposure between 
oral dosing wi th solution and tablet formulat ions. Subsequently, the pr edicted TAK -935 pl asma 
concentrations were modeled with PD (24HC and PET occupancy) data to assess target 
engagement. The relationship between TAK- [ADDRESS_108496] response m odel. This PK/PD/EO model was used to select the doses for 
the current study . The m odel-based simulat ions were performed for both QD and BID dosing 
regimens wit h the same daily dose in adult subjects, and the BID regimen was selected over QD 
regimen due to its lo wer variabilit y on the expected EO, PK, and PD parameters and a more 
sustained period during a dosing interval with EO above 65%.
[IP_ADDRESS] Dose Selection Procedures
The pl anned doses are based on predict ions from the available PK/PD/EO model. A TAK -935 
100mg tablet, administered as 1, 2, or 3 tablets corresponding to the different dose levels, will be 
used for dosing in adult subjects.
The EO levels and planned TAK -935 doses are shown for each part of the study  inTable 6.a.
Table 6.a Planned TAK -935 BID Doses and Associated Estimated EO Levels
TAK -935 BID Dose
(mg)Average EO
Level (%) (a)
300 85-95
200 80-90
100 70-80
(a) Average EO% at steady state during a dosing interval.
The invest igator, in consultat ion with the sponsor, may decide to reduce the IP (TAK -935 or 
placebo) during Part 1 and TAK -935 during Part 2 dose at any  time during the study , in the event 
of any safet y or tol erabilit y concerns. In Part 1, the planned starting dose of TAK -935 for adul t 
subjects is 100 mg BID to achieve an average steady -state EO of approximately  70% to 80%. If 
well tolerated, this dose will be increased to 200 mg BI D on Day  11 and subsequent ly to 300 mg 
BID on Day 21; the average steady -state EO at these doses are expected to be approximately 80% 
to 90% and 85% to 95%, respectively ( Table 6.a).
TAK-935 
Study No. TAK-935- 2001 Page 30 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIALIn Part 2, the planned starti ng dose of TAK- 935 for all s ubjects, including those who received 
placebo in Part 1, is 200 mg BID to be increased to 300 mg BID. The dose may be decreased at any 
time due to safety or tolerability concerns.
6.2.3 Endpoints
[IP_ADDRESS] Safety Endpoints
The safety-related endpoints of TEAEs, clinical laboratory test results, vital sign measurements, 
C-SSRS, and ECG parameters selected for this study are standard methods for assessing safety and 
tolerability in clinical studies. The ABC-C is a sta ndard tool for measuring the severity of a range 
of problem behaviors commonly observed in i ndividuals with intellectual and developmental 
disabilities.
[IP_ADDRESS] PK Endpoints
The secondary PK endpoints selected for this study, C max, AUC 0-tau, Cav,ss, and C trough are common 
PK parameters used to describe the steady-state exposure of a study drug following multiple doses 
in clinical studies. Additional population PK parameters will be included in the population PK 
model used to characterize the TAK-935 concen tration-time profile and will be reported in the 
population PK report.
[IP_ADDRESS]
6.2.3.4CCI
CCICCI
CCI
TAK -935 
Study No. TAK -935-2001 Page 31of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL6.3 Premat ure Termination or Suspension of Study or Study Site
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be co mpleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  termination of the study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  drug that 
indicates a change in the known risk/benefit profile for TAK- 935, such that the risk is no 
longer acceptable for subjects participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study  objectives or compromises subject safet y.
6.3.2 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminat ed prematurely or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwise permitted by  [CONTACT_39778].
6.3.[ADDRESS_108497] (IRB), or a regulatory authority elects 
to terminate or suspend the study or the participat ion of a study site, a study -specific procedure for 
early terminat ion or suspensio n will be provided by [CONTACT_456]; the procedure will be fo llowed by 
[CONTACT_57791] n or study  suspensi on.
TAK -935 
Study No. TAK -935-2001 Page 32of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/ WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be confirmed before the first dose of study  drug.
7.[ADDRESS_108498] eligibilit y is determined according to the following criteria before entry  into the study :
1.In the opi[INVESTIGATOR_3078] n of the invest igator, the subject or subject’s legally acceptable representative is 
capable of understanding and co mplying with protocol requirements.
2.The subject or the subject’s legally acceptable representative signs and dates a written, 
inform ed conse nt form and any requi red privacy  authori zation before the init iation of any 
study  procedures, including request ing that a subject fast for any clinical laboratory 
evaluat ions. An assent should be obtained from the subject, if possible. If the subject canno t 
provi de assent (ie, due to developmental status), the investigator should document why assent 
was not obtained. For subjects with G -tube/PEG tube, a separate supplemental consent form 
will be signed by [CONTACT_423]/caregiver and attached to the general co nsent.
3.The subject is a male or female aged ≥18 and ≤[ADDRESS_108499] has a documented clinical diagnosis o f developmental and/or epi[INVESTIGATOR_98600] h bilateral motor seizures , defined as an average of ≥[ADDRESS_108500] igator’s assessment, and a monthly average of ≥[ADDRESS_108501].
Developmental and/or epi[INVESTIGATOR_98601]:
Subjects with an established diagnosis o f the following: for example, Lennox -Gastaut 
Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex, OR
Retrospectively  including:
History  of special educat ion classes, OR
Formal IQ <70, OR
Generalized background slowing (posterior dominant rhy thm [PDR] persistent ly 
<8Hz) on interictal EEG,
AND
Epi[INVESTIGATOR_98602] a brain injury  acquired after age [ADDRESS_108502] is taking 1 to 4 AEDs at a stable dose for ≥4 weeks before Screening (Visi t 1), and 
the subject or subject’s legally acceptable representative is willing to keep the regimen(s) 
stable throughout the study . For the purposes of this study  ketogeni c diet and vagus nerve 
stimulat ion will not be considered AEDs.
TAK -[ADDRESS_108503] has an av erage of ≥1 bilateral  motor seizure per m onth during the 4 -week 
Baseline Period (ie, drop sei zures, toni c-clonic, tonic, bilateral  clonic, atonic, 
myoclonic-atoni c, my oclonic-tonic-clonic, f ocal seizures wit h bilateral hy perkinet ic motor 
features). Drop se izures are defined as a seizure invo lving the ent ire body , trunk or head that 
leads to a fall, injury, slumpi[INVESTIGATOR_10714] a chair, or head hitt ing the surface, or could have led to a fall 
or injury , depending on the posi tion of  the subject at the time of the atta ck or spell. Drop 
seizures will be captured separately  (eg, toni c seizures l eading to a drop will be captured as a 
drop). If the subject has <[ADDRESS_108504] of childbearing potential*must have a negative serum pregnancy (human 
chori onic gonadotropin [hCG]) test at Screening (Visit 1) and a negative urine pregnancy test 
before Rando mizat ion (Vi sit 2). If  urine cannot be collected, the results of the serum 
pregnancy test obtained at Vis it [ADDRESS_108505] of childbearing potential* who is sexually act ive with a nonsterilized* male 
partner agrees to use routinely an adequate method of contraception* fro m signin g of informed 
consent throughout the duration of the study  and for [ADDRESS_108506] who is nonsterilized *and sexually active wit h a female partner of childbearing 
potenti al*agrees to use adequate contraception *from signing of inf ormed consent throughout 
the duration of the study  and for [ADDRESS_108507] dose.
*Definit ions and acceptable methods of contraceptio n are defined in 
Secti on9.1.[ADDRESS_108508] ion9.1.13 .
10.Subjects and/or subjects’ caregivers must agree to not post any subject’s personal medical data 
related to the study or informat ion related to the study on any web site or social media site (eg, 
Facebook, Twitter) until the study  has been completed.
11.For subjects with G -tube/PEG tube, G -tubes /PEG tubes should have been placed and been 
funct ioning for at least [ADDRESS_108509] who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.The subj ect has been part of a clinical study  involving another invest igational product in the 
previous [ADDRESS_108510] was admitted to a medical facilit y for treatm ent of status epi[INVESTIGATOR_98603] 3 months before Screening (Visit 1).
4.The subject had a vagal nerve stimulator implanted within 6 months before Screening (Visit 1) 
and settings have been changed wit hin 1 month of the Screening Visit (Visit 1) and/or are 
anticipated to change during the study .
TAK -[ADDRESS_108511] is on a ketogenic diet that has been started within 6 mo nths of the Screening Visit  
(Visit1), has been changed withi n 1 m onth of the Screening Visit (Visit 1), or is anticipated to 
change during the study .
6.The subject is an immediate family member, study site emplo yee, or i s in a dependent 
relationship with a study  site em ployee who i s involved in the conduct of this study  
(eg,spouse, parent, child, sibling) or may consent under duress .
7.The subject has unstable, clinically significant neurologic (other than the disease being 
studi ed), psychiatri c, cardi ovascular, pulmo nary, hepati c, renal, m etabo lic, gastrointest inal,
urologic, immuno logic, hematopoi etic, or endocrine disease or other abnormalit y, which m ay 
impact the abilit y of the subject to participate or potent ially confound the study results. It is the 
responsibilit y of the invest igator to assess the clinical sign ificance; however, consultat ion with 
the Medi cal Monitor m ay be warranted.
8.The subject has degenerat ive eye disease.
9.The subject has a history  of suicidal behavior or any  suicidal  ideati on of  type 4 or 5 on the 
C-SSRS at Screening (Visit 1). If the subject is unable to comply with the C -SSRS due to 
developmental status, a parent proxy  may be used for the com pletion of  the C -SSRS. The 
Invest igator may also use clinical judgment, which must then be documented in the source 
docum ent.
10.Positive for hum an immunod eficiency virus, hepatit is B, or hepatit is C infect ions. (Note that 
subjects who have been vaccinated against hepatit is B [hepat itis B surface ant ibody  
{Ab} -positive] who are negative for other markers of prior hepatit is B infect ion [eg, negative 
for hepat itis B core Ab] are eligible. Also note that subjects who are posit ive for hepat itisC Ab 
are eligible as long as they  have a negat ive hepat itis C viral load by [CONTACT_98630] [qPCR]). 
11.The subject has an abnormal and clinically sig nificant ECG at Screening (Visit 1), in the 
opi[INVESTIGATOR_3078] n of the invest igator, for example, second or third-degree heart bl ock or a corrected QT 
interval  (QTc) >[ADDRESS_108512] resul ts at Screening (Vi sit 1) that suggest a 
clinically significant underlying disease. If the subject has alan ine aminotransferase (ALT) 
and/or aspartate aminotransferase (AST) >2.5 × the upper limit o f normal (ULN), the Medical 
Moni tor shoul d be consul ted.
13.The subject has a known hypersensit ivity to any  component of the formulat ion of TAK -935.
14.The subject has rec eived any excluded medicat ions, procedures, or treatments during the time 
periods listed in Section7.3.
TAK -[ADDRESS_108513] ical Manual of Mental Disorders, Fifth Edit ion, wi thin the previous 2 years before 
Screening (Visit 1). Medical marijuana use is allo wed.
16.If female, the subject is pregnant or lactating or intending to become pregnant before, during, 
or wi thin 30 days after participat ing in this study; or intending to donate ova during such time 
period.
17.If male, the subject intends to donate sperm during the course of this study  or wi thin 30days 
after the l ast dose of study  drug.
7.3 Excluded Medications, Procedures, and Treatments
The fo llowing m edicat ions and products are excluded fro m the Screening Visit (Visit 1) until the 
end of the Fo llow-up Visi t (Vi sit 9):
Intermittent use of benzodiazepi[INVESTIGATOR_98604] ≥3 times a week. Chronic 
benzodiazepi[INVESTIGATOR_98605].
Stiripentol
Subjects should be advised to not consume alcohol or drugs such as cannabis (medical marijuana is 
allowed) during the study . Subjects m ust be instructed not to take any  medicat ions, including 
over-the-counter products, without first consult ing with the invest igator.
7.[ADDRESS_108514] be recorded in the electronic case 
report form (eCRF) at each PK/PD sampling visit. Subjects and/or subjects’ caregivers should be 
instructed to maintain the same dose administration time for the concomitant AEDs through out the 
study , if possible. It is recommended that subjects remain upright (seated, standing, or ambulatory) 
for approximately  1hour after study  drug dosing on the PK sampling days, if possible. For 
subjects receiving study  drug via G -tube/PEG tube, other medications or enteral  feeds shoul d not 
be given concurrent ly.
Subjects who are on a ketogenic diet must maintain stable dietary habits throughout the study. The 
ketogenic diet should not be altered during the study .
7.[ADDRESS_108515]’s health or the subject is unwilling t o 
continue because of the AE.
Liver Funct ion Test (LFT) Abnormalit ies
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 9.1.11 ), if the following circumstances occur at any 
time during study  drug treatm ent:
ALT or AST >8 × ULN, or
ALT or AST >5 × ULN and persist s for >[ADDRESS_108516] >3 × ULN in conjunct ion with elevated total  bilirubin >2 × ULN or 
internat ional norm alized rati o (INR) >1.5, or
ALT or AST >3 × ULN with appearance of fat igue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
2.Significant Protocol Deviat ion. The discovery after the first dose of study drug that the subject 
failed to meet protocol entry criteria or did not adhere to protocol requirements, and continued 
participat ion poses an unacc eptable risk to the subject’s healt h.
3.Lost to Follow -up. The subject did not return to the clinic and attempts to contact [CONTACT_39783]. Attempts to contact [CONTACT_39784]’s source 
docum ents.
4.Withdrawal by [CONTACT_98631]. The subject wishes to withdraw (or subject’s legally acceptable 
representative wishes to withdraw the subject) from the study .
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded. Withdrawal due to an AE 
shoul d not be recorded in the “vo luntary withdrawal ” category . Similarly , lack of efficacy  
shoul d not be recorded in the “vo luntary withdrawal ” category .
5.Progressive Disease. Clinically significant worsening in seizure frequency  as judged by  [CONTACT_98632] [ADDRESS_108517] is found to be pregnant .
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.13 .
9.Other.
TAK -935 
Study No. TAK -935-2001 Page 37of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALNote: The specific reasons should be recorded in the “specify” field of the eCRF.
7.[ADDRESS_108518]’s study participat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section 7.5. In addition, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
[CONTACT_3170]. In addit ion, efforts should be made to perform all procedures scheduled for the 
Final Visit (at time of wit hdrawal), including dose de -escalat ion, as appropriate, fo llowed by  [CONTACT_941] 
30-day Follow-up Peri od.Up to [ADDRESS_108519] ion contains informat ion regarding all medicat ion and m aterials provi ded di rectly by [CONTACT_103], and/or sourced by  [CONTACT_39785] m eans, that are requi red by [CONTACT_23643] , including 
important sections describing the management of study  material.
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s protocol , the term  study  drug refers to all or any  of the drugs defined below.
[IP_ADDRESS] Study Drug
The sponsor will supply the study  sites wi th TAK-[ADDRESS_108520] ion 
seal and child- resistan t caps. Each bottl e will contain a label that includes pertinent study  
inform ation and caution statements. The label text will be in E nglish. The bottles to be used will be 
ident ifiable by a unique ident ification number and managed by [CONTACT_98633]  (IVRS)/interactive web response system (IWRS).
For subjects receiving study  drug via G -tube/PEG tube, tablets will be crushed, suspended in 
water, and the suspension will be administered via the G -tube/PEG tube using a syringe. Complete 
instructi ons will be provided to subjects/caregivers in a document provided outside of the protocol.
[IP_ADDRESS] Rescue Medication
Rescue medicat ion will be used in case of major seizures, according wit h the j udgment of the 
investigator and based on evidence o f prior positive responses o f each subject. Rescue medicat ion 
will not be supplied by [CONTACT_456].
[IP_ADDRESS] Sponsor -Supplied Drug
Sponsor -supplied drugs referenced in other sections of the protocol are the following :
TAK -935 100 m g tablets.
Matching placebo tablets.
8.1.[ADDRESS_108521] be stored at 20°C to 25°C 
(68°F -77°F). Excursi ons are permitted between 15°C and 30°C (59°F -86°F).
Study  drug, must be kept in an appropriate, limited -access, secure place unt il it is used or returne d 
to the sponsor or designee for destruction. Study  drug m ust be stored under the conditions 
specified on the label, and remain in the original container unt il dispensed. A daily temperature log 
of the drug storage area must be maintained every  working day .
TAK -[ADDRESS_108522] and/or subject’s caregiver will be instructed to administer study  drug, orally or via 
G-tube/PEG tube, at the same time each day with or wi thout food. The study  site personnel will 
indicate how many tablets should be taken per day on the bottle label, per informat ion provided by 
[CONTACT_21926]/IWRS . For each visit with scheduled PK blood sampling, the morning dose of study 
drug will be administered in the cli nic. The time of the last meal relative to dosing must be 
recorded in the eCRF at each PK/PD sampling visit.
For G -tube/PEG -tube administration, the required number of tablets will be ground into a powder, 
suspended in water, and the suspensio n will be adm inistered via G -tube/PEG -tube using a syringe. 
Com plete instructi ons for administering the drug via G -tube/PEG -tube will be provided to 
subjects/caregivers in a document provided outside of the protocol.
The invest igator or designee will instruct the subje ct and/or subject’s caregiver on the dosing 
procedures and study  drug storage requirements. Subjects and/or subjects’ caregivers shoul d 
return unused study  drug at each study  visit to all ow the investigator or designee to evaluate 
subjects’ compliance with the dosing instructions.
The pl anned daily  dose and tabl et count to be administered to subjects in each part of the study  is 
shown in Table 8.a.
Table 8.a Planned Dose and Regimen
Study Part Planned Doses Treatment Description
Part 1
(double -blind dose 
escalation )TAK -935 200 mg/day ( 100 mg BID )
Matching Placebo BID
TAK -935 400 mg/day ( 200 mg BID )
Matching Placebo BID
TAK -935 600 mg/day ( 300 mg BID )
Matching Placebo BID1 TAK -935 100 mg tablet BID for 10 days
1 placebo tablet BID for 10 days
2 TAK -935 100 mg tablets BID for 10 days
2 placebo tablets BID for 10 days
3 TAK -935 100 mg tablets BID for 10 days
3 placebo tablets BID for 10 days
Part 2 (open -label
dose escalation)TAK -935 400 mg/day (200 mg BID)
TAK -935 600 mg/day (3 00 mg BID)2 TAK -935 100 mg tablets BID for 10 days
3 TAK -935 100 mg tablets BID for 44 days
Note 1: The dose of IP will be gradually escalated during Parts 1 and 2, provided there are no safety or tolerability 
concerns. At the end of Part 2, the dose of TAK -935 will be de -escalated before dosing is discontinued. See Section 
6.1for details of the dose escalation and de -escalation procedures.
Note 2: The investigator, in consultation with the sponsor, may reduce the IP (Part 1) or TAK -935 (Part 2) dose at any 
time in the event of any safety or tolerability concerns, including to the [ADDRESS_108523] according to the 
study  protocol .
TAK -935 
Study No. TAK -935-2001 Page 40of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALAll cases of overdose (with or without associated AEs) will be documented in the eCRF. Cases of 
overdose without manifested signs or symptoms are not considered AEs. AEs associated with an 
overd ose will be documented on the AE eCRF page according to Section 10.2.1 .
Serious adverse events (SAEs) associated with overdose should be reported ac cordi ng to the 
procedure outlined in Sect ion 10.2.[ADDRESS_108524] igator’s designee will access the IVRS/IWRS at the Screening Visit (Visit 1) 
to obtain the subject numbe r. At Randomizat ion (Vi sit 2), the invest igator or the investigator’s 
designee will use the IVRS/IWRS to randomize eligible subjects into the study. During this 
contact, the invest igator or designee will provide the necessary subject -ident ifying informat ion, 
including the subject number assigned at Screening. The medication ident ification (ID) number of 
the study  drug to be dispensed will then be provided by  [CONTACT_21926]/IWRS. At subsequent 
drug-dispensing visits, the invest igator or designee will again contact [CONTACT_21926]/IWRS to request 
additional study  drug for a subject. The medicat ion ID number of the study  drug to be di spensed 
will again be provided by [CONTACT_21926]/IWRS. The medicat ion ID number will be entered onto the 
eCRF. If sponsor -supplied drug (TAK -[ADDRESS_108525] acebo tabl ets) i s lost or 
damaged, the si te can request a replacement from the IVRS/IWRS (refer to the IVRS/IWRS 
manual provided separately ).
Each subject and/or subject’s caregiver shoul d be instructed as follows:
Keep sponsor -supplied d rugs in ori ginal  containers until the time of dosing.
Administer study  drug as instructed. If the subject misses a dose, he or she should not be give n 
twice the dose the next day . 
Store sponsor -supplied drugs according to the label and keep them out of the reach o f children.
Return sponsor -supplied drugs at each clinic visit.
On the dosing card provided wit h each supply of drug, record the AM and PM daily doses and 
days/times the drug has been down -titrated, including during the de -escalat ion porti on of  the 
study . 
In addit ion to the above, subjects/caregivers will be provided co mplete i nstructi ons on preparing 
the study  drug for administration via G -tube/PEG -tube in a document provided outside of the 
protocol . They  shoul d follow these instructi ons carefull
y.
8.3 Randomization Code Creation and Storage
Randomization personnel o f the sponsor or designee will generate the randomization schedule. All 
rando mizat ion informat ion will  be stored in a secured area, accessible only  by [CONTACT_39792].
TAK -935 
Study No. TAK -935-2001 Page 41of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALStudy  drug will be administered in a double -blind manner in Part 1 and in an open -label manner in 
Part 2. The study  drug blind will be maintained using the IVRS/IWRS . The principal invest igator 
at each study  site will receive instructions for obtaining the study  drug assignment through the 
IWRS. During regularly  scheduled m onitoring visits, a study mo nitor from the sponsor or a 
designee will perform an inventory  of assigned and unassigned bottles o f study  drug. All 
assigned/unassigned study drug bottles wil l be reconciled and returned to the sponsor or a designee 
before study  closure.
8.[ADDRESS_108526]. If possible, the 
sponsor/designee should be notified before the study drug blind is broken. If a medical emergency 
requi ring unblinding occurs, the invest igator (or designee) at the site will contact [CONTACT_98634] (see [COMPANY_005] Medi cal Moni tor contact [CONTACT_98635] 1.1) to assess the 
necessit y to break the study  drug blind.
For unblinding a subject, the invest igator can obtain the study drug blind informat ion by [CONTACT_98636]/IWRS. The sponsor/designee must be notified immediately if the study  drug blind is 
broken. The date, time, and reason the blind was broken must be recorded in the source documents 
and on the appropriate eCRF.
If any site personnel is unblinded, study  drug m ust be de -escalated in consultation wit h the 
Medical Monitor and the subject must be withdrawn fro m the study . The reason for withdrawal 
shoul d be recorded as “Protocol Deviat ion.” Su
bjects who are withdrawn early fro m the study  
shoul d undergo all procedures scheduled for the Final Visit at the time of wit hdrawal.
8.[ADDRESS_108527] ensure that the sponsor -supplied drug is used in accordance wit h 
the protocol and is dispensed only to subjects enro lled in the study . To docum ent appropri ate use 
of sponsor -supplied drug (TAK -935 100 m g and matching placebo tablets), the invest igator or 
designee must maintain records of all sponsor -supplied drug delivery to the site, site inventory, 
dispensat ion and use by [CONTACT_6992], and return to the sponsor or designee.
Upon re ceipt of sponsor -supplied drug, the invest igator or designee must verify the contents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and the 
study  drug is in good condit ion. If quant ity and condit ions ar e acceptable, investigator or designee 
shoul d acknowl edge the recei pt of the shipment by [CONTACT_98637]/IWRS. If there are any  
discrepancies between the packing list versus the actual product received, [COMPANY_005] must be 
contact[CONTACT_45320]. The packing list should be filed in the investigator’s essent ial 
docum ent file.
TAK -[ADDRESS_108528] maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her entire participat ion in the study . Proper dru g 
accountabilit y includes, but is not limit ed to the following:
Continuously mo nitoring expi[INVESTIGATOR_82246].
Frequent ly verifying that actual inventory  matches docum ented inventory .
Verifying that the log is completed for the drug lot (or medication ID number) used to prepare 
each dose.
Verifying that all containers used are documented accurately on the log.
Verifying that required fields are co mpleted accurately and legibly.
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The I VRS/IWRS will include all required information as a separate entry for each subject to who m 
sponsor -supplied drug is dispensed.
The invest igator or designee must record the curr ent inventory  of all sponsor -supplied drugs 
(TAK -935 100 m g and m atching placebo tablets) on a sponsor -approved drug accoun tabilit y log. 
The fo llowing inform ation will be recorded at a minimum: protocol number and tit le, name [CONTACT_39843], site ident ifier and number, descript ion of sponsor -supplied drugs, expi[INVESTIGATOR_5695], date 
and amount dispensed including init ials or signature [CONTACT_39844], and the 
date and amount returned to the site by [CONTACT_423], including the init ials or signature [CONTACT_98656] -supplied drug. The log should include all required information as a separate 
entry  for each subject to whom sponsor -supplied drug is dispensed.
All study  drug that was not returned to the site by  a subject m ust be inves tigated by  [CONTACT_98638].
Before site closure or at appropriate intervals, a representative fro m the sponsor or its designee will 
perform  sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied drugs 
are returned to the sponsor or its designee for destruction. The invest igator or designee will retain a 
copy  of the documentati on regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
The invest igator will be notified of any retest date extensio n of sponsor -supplied drug during the 
study  conduct. On expi[INVESTIGATOR_98606] m the sponsor or designee, the site must complete all 
instructi ons outlined in the notificat ion, including segregation of expi[INVESTIGATOR_98607] -supplied drug
for return to the sponsor or its designee for destruction.
In the event of expi[INVESTIGATOR_57772] n of sponsor -supplied drug already  at the study  site, 
sponsor -supplied drugs may be relabele d with the new expi[INVESTIGATOR_87770]. In such cases, 
[COMPANY_005] or i ts desi gnee will  prepare addi tional labels, certificates of analyses, and all necessary  
docum entati on for com pletion of  the procedure at the sites.
TAK -[ADDRESS_108529] ion
 15.2.
[IP_ADDRESS] Study Informed Consent Procedure
Inform ed consent m ust be obtained before the subject enters into the study , and before any  
protocol -directed procedures are performed, including request ing th at a subject fast for clinical 
laboratory  evaluat ions.
The informed consent form  must be signed by [CONTACT_29159]’s legally acceptable 
representative. A verbal or written subject assent should be obtained fro m the subject in the event 
the subje ct is not capable of providing an informed consent. If the subject is not capable of 
provi ding an assent, the reason should be documented by  [CONTACT_3170].
In addit ion, a separate supplemental informed consent form ( ICF) providing informat ion on 
G
-tube/ PEG -tube administration of study  drug will be signed.
A unique subject ident ificat ion (ID) number (subject number) will be assigned to each subject at 
the time that informed consent is obtained; this subject number will be used throughout the study.
[IP_ADDRESS] PGx Informed Consent Procedure
A separate informed consent form pertaining to collect ion, storage, and analysis of the PGx blood 
samples must be obtained before collect ing these samples in this study. The provisio n of consent to 
collect and analyze the PGx sampl e is independent of consent to the other aspects of the study .
9.1.[ADDRESS_108530]. Hei ght and wei ght will be collected at Screening (Visit 1).
Medical history  to be obtained will include determining whether the subject has any  significant 
condi tions or di seases rel evant to the di sease under study  that resolved at or before signing of 
inform ed consent. Ongoing condit ions are considered concurrent medical condit ions (see 
Secti on9.1.10 ).
Medicat ion history  informat ion to be obtained includes any medica tion rel evant to eligibilit y 
criteria and the efficacy or safet y evaluat ions stopped at or within [ADDRESS_108531] of the following body  systems: (1) ears, nose, throat; 
(2)cardiovascular system; (3) respi [INVESTIGATOR_36517]; (4) gastrointest inal system; (5) dermatologic 
system; (6) extremit ies; (7) musculoskeletal system; (8) lymph nodes; (9) psychiatri c status; and 
(10) other. All examinat ions are to be performed by [CONTACT_093]. The physical examinat ion 
must be captured in the source document and eCRF.
9.1.[ADDRESS_108532] ion, cranial nerves, motor function (including 
strength and reflexes), and sensat ion.
As part of the neuro logical exam, visi on testing i s recommended to include f undoscopy  and best 
corrected visual acuit y using a pocket vision screening card, if possible.
9.1.[ADDRESS_108533] is wearing indoor clothing and with shoes 
off. If unable to obtain height or weight , data m ay be collected from  other sources (eg, medical 
records or the subject’s caretaker). The investigator must document in the source document the 
reason for not obtaining height or weight (eg, the subject is in a wheelchair). The BMI is calculated 
using metric units wit h the formula provided belo w. The [COMPANY_005] standard for collect ing height is 
centimeters without decimal places and for weight is kilograms (kg) with [ADDRESS_108534]. BMI 
shoul d be derived as follows:
Note that although height is reported in centimeters, the formula uses meters, which can be 
determined fro m centimeters by [CONTACT_45322] 100. Thus, for example, if height=176 cm 
(1.76 meters) and weight=79.2 kg, then BMI=79.2/1.762=25.[ZIP_CODE] kg/m2.
9.1.6 Vital Sign Procedure
Vital signs to be measured are oral body  temperature, si tting (after resting for 5 minutes) blood 
pressure, heart rate (beats per minute), and sitting respi[INVESTIGATOR_2842]. Heart rate and blood pressure 
will also be measured after [ADDRESS_108535] document in the source document the reason for not obtaining a standing or 
supi[INVESTIGATOR_9204] (eg, the subject is in a wheelchair).
Vital signs shoul d be m easured at the sam e time of day  across visits, if possibl e. When vital signs 
are scheduled at the same time as blood draws, the blood draw will take priorit y and vital signs will 
be obtained within 0.[ADDRESS_108536] and/or caregiver at each clinic visit to record daily 
AM and PM study drug administration throughout the study, including changes in dosing regimen 
(de-escalation) that may occur between visits a nd during the de-escalation period of the study.
9.1.[ADDRESS_108537] taken any medication 
other than the study drug (used from signing of  informed c onsent through the e nd of the study), 
and all medication including vitamin supplements, over-the-counter medications, and oral herbal 
preparations, must be recorded in the source document and eCRF. Docu mentation w ill include 
generic medication name, dose, unit, frequency, route of administration, start and end dates, and 
reason for use.
9.1.10 Documentation of Conc urrent Medical Conditions
Concurrent medical conditions are those significant ongoi ng conditions or diseases that are present 
at signing of informed consent. These include clinically significant laboratory, ECG, or physical 
examination abnormalities noted at Screening (Visit 1), according the judgment of the CCI
CCI
TAK -935 
Study No. TAK -935-2001 Page 46of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALinvestigator. The condit ion (ie, diagnosis) shoul d be described and recorded on the Medical 
History  form.
9.1.11 Procedures for Clinical Laboratory Samples
Blood and urine samples are to be collected at the time points stipulated in the Schedule of Study  
Procedures ( Appendix A). Blood sam ples for hematol ogy and serum  chemistry  tests are to be 
collected after an overnight fast of ≥[ADDRESS_108538], the maximum vo lume of blood collected at any  single visit will be 
approximately  71 mL, and the approximate total volume of blood collected over th e course of the 
study  will be 230 mL ( Table 9.a).
Table 9.a Approximate Blood Volume
Sample TypeSample
Volume
(mL)Number of Samples (a)Total 
Volume
(mL)Screening 
Visit Part 1 Part 2Follow -up
Visit
HIV, HBsAg, HCV (b) 6 1 --- --- --- 6
HCV RNA detection by [CONTACT_62865] (c) 6 1 --- --- --- 6
FSH (d) (d) 1 1 (d)
Estradiol (e) 2 1 1 4
Serum chemistry (f) 6 1 1 2 --- 24
Hematology 2 1 1 2 --- 8
Plasma sample for TAK -935 PK analysis 4 --- 8 3 --- 44
Plasma sample for AED analysis 4 --- 3 3 1 28
Plasma sample for PD analysis (g) 4 2 16 6 2 104
Blood sample for DNA PGx 6 --- 1 --- --- 6
Blood sample for RNA PGx (g) 2.5 --- 2 2 --- 10
Total Blood Volume (mL) 240
---=not applicable.
(a) Does not include blood draws at any unscheduled visits.
(b) One 2- mL blood sample for each test.
(c) Subjects who are positive for hepatitis C Ab should return to the clinic for an unscheduled visit to provide a blood 
sample for HCV qPCR.
(d) For diagnostic purposes in female subjects only; sample will be run from serum chemistry volume (no extra 
volume required).
(e) In female subjects only.
(f) Includes serum pregnancy test for female subjects of childbearing potential.
(g) Two blood samples per scheduled time.
TAK-935 
Study No. TAK-935- 2001 Page 47 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIALThe clinical laboratory tests to be performed are listed in  Table 9.b.
Table 9.b Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis (a) Study Specific
RBC
WBC with differential (% and absolute)HemoglobinHematocritPlateletsPT/INRaPTTALT
AlbuminAlpha-1-acid glycoproteinAlkaline phosphataseASTTotal bilirubinTotal proteinCreatinineBlood urea nitrogenCreatine kinase
GGT
PotassiumSodiumGlucoseChlorideBicarbonateCalciumTotal cholesterolHDL cholesterolLDL cholesterolTriglyceridesFSH (c)
Estradiol (d)pH
Specific gravityProteinGlucoseBlood Nitrite
Microscopic Analysis: (b)
RBC/high power field
WBC/high power fieldEpi[INVESTIGATOR_1663], casts etcPlasma
Plasma (Concomitant AEDs)
Carbamazepi[INVESTIGATOR_98608]10-hydroxycabazepi[INVESTIGATOR_050] (metabolite of oxcarbazepi[INVESTIGATOR_050])Felbamate
Diagnostic Screening
Serum Urine (a)
HIV Drug screen including amphetamines, barbiturates, 
benzodiazepi[INVESTIGATOR_1651], cannabinoids, cocaine, opi[INVESTIGATOR_858], alcohol, and cotinine
hCG (for pregnancy) (f)HBsAg and anti-HCV
HCV RNA detection by [CONTACT_62865] (e)
hCG (for pregnancy) (f)
aPTT= activated partial thromboplastin time, FSH=follicle-stimulating hormone, GGT= γ-glutamyl transferase, 
HDL=high-density lipoprotein, LDL=low-density lipoprotein, PT=prothrombin time, RBC=red blood cell; WBC=white blood cell.(a) If urine cannot be collected at the time of the Screening Visit or other Visits due to the subject’s cooperation or 
because the subject is wearing a diaper, it is acceptable for th e subject to continue in the study and the reason should be 
documented in the source document.(b) Only if dipstick results are positive.(c) For diagnostic purposes in female subjects only.(d) In female patients only(e) Subjects who are positive for hepatitis C Ab should return to the clinic for an unscheduled visit to provide a blood sample for HCV qPCR.(f) Only for female subjects of childbearing potential. If urine cannot be collected at Visit 2, the reason should be documented in the source document and the results of the serum pregnancy test obtained at Visit [ADDRESS_108539] >3×ULN, fo llow-up laboratory  tests (at a mi nimum , serum  
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed preferably 
within 48 to 72 hours and no later than 5 day s after the abnormalit y was noted.
(Please refer to Section 7.5for discont inuat ion criteria and Secti on 10.2.[ADDRESS_108540] >3×ULN in conjunct ion with total  bilirubin >2×ULN.)
If the ALT or AST remains elevated >3×ULN on these [ADDRESS_108541] details and possible 
alternat ive et iologies. The abnormalit y should be recorded as an AE (please refer to Section
 10.2.3
for reporting requirements).
If urine cannot be collected due to the subject’s cooperation or because the subject is wearing a 
diaper, the reason should be documented in the source document and, for female subjects, the 
resul ts of the serum  pregnancy  test obtained at Visit [ADDRESS_108542] dose of study  drug, nonsterilized** male subjects who are sexually  active wi th a female 
partner of childbearing potential* must use barrier contraception (eg, condom with spermic idal 
cream  or jelly). In addit ion, they  must be advised not to donate sperm during this period. Females 
of childbearing potential who are partners of male subjects are also advised to use addit ional 
contraception as shown in the list of adequate contracept ion below.
From  signing of informed consent, throughout the duration of the study , and for [ADDRESS_108543] dose of study  drug, female subjects of childbearing potential* who are sexually act ive with a 
nonsterilized male partner** must use adequate c ontraception. In addit ion, they  must be advised 
not to donate ova during this period.
*Females NOT of childbearing potential are defined as those who have been surgically sterilized 
(hysterectomy, bilateral oophorectomy, or tubal ligation) or who are postm enopausal  (eg, defined 
as ≥[ADDRESS_108544] regular menses with an FSH >40 IU/L or ≥[ADDRESS_108545] regular menses, 
confirmed before any study  drug i s administered).
**Sterilized males should be ≥[ADDRESS_108546] o btained 
docum entati on of  the absence of sperm in the ejaculate.
An acceptable method of contraception is defined as one that has no higher than a 1% failure rate 
per year when used consistent ly and correctly. In this study, where medicat ions and devices 
containing hormones are excluded, the only  acceptable methods of contraception are as follows:
TAK -935 
Study No. TAK -935-2001 Page 49of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALBarrier methods (each time the subject has intercourse):
Male condom PLUS spermicide.
Cap (pl us spermicidal cream or jelly ) PLUS male condom  and spermicide.
Diaphragm (plus spermicidal cream or jelly) PLUS male condo m and spermicide.
Intrauterine devices:
Copper T PLUS condom or spermicide.
Sterilization:
Bilateral tubal occlusio n.
Vasectomized partner (provided that the partner is the sole sexual partner of the s tudy 
participant and the absence of sperm in the ejaculate has been confirmed).
Abstinence:
Sexual abst inence, if it is the preferred and usual lifest yle of the subject, will be considered an 
acceptable method of contraception on a case -by-case basis upon prior approval  by [CONTACT_5134]. Subjects practicing abst inence as a method of contraception must refrain 
from heterosexual intercourse throughout the duratio n of the study  and f or [ADDRESS_108547] at 
Screening (Visit 1) a nd a negative urine hCG pregnancy test on Day  1 (Visi t 2), before receiving 
any dose of study  drug. During the course of the study , subjects will receive cont inued guidance 
with respect to the avo idance of pregnancy and sperm donation as part of the study procedures. An 
additional serum  hCG pregnancy test will be performed at the Final Visit.
9.1.[ADDRESS_108548]’s partner.
If the pregnancy  occurs during administration of active study  drug, for exam ple, after Visit [ADDRESS_108549] and/or female partner of a male subject agrees to the primary care physician 
being informe d, the invest igator should notify the primary care physician that the subject/female 
partner of the subject was participat ing in a clinical study  at the time she became pregnant and 
provi de details o f treatm ent the subject received (blinded or unblinded, a s applicable).
All reported pregnancies, including those in female partners of male subjects, will be followed up 
to final outcome, using the pregnancy form. The outcome, including any premature terminat ion, 
must be reported to the sponsor. An evaluat ion after the birth of the child will also be conducted.
9.1.[ADDRESS_108550] igator (or a qualified observer at the study site) will interpret the ECG using 1 
of the fo llowing categori es: wi thin normal limits, abnormal but not clinically significant, or 
abnorm al and clinically  significant. The interpretatio n of the ECG will be recorded in the source 
docum ents and in the eCRF. The time that the ECG wa s performed will be recorded. The 
following parameters will be recorded on the eCRF from the subject’s ECG trace: heart rate, RR 
interval , PR interval , QT interval, QRS interval wit h QTcF, and corrected QT interval . ECG traces 
recorded on thermal paper will be photocopi [INVESTIGATOR_98609].
9.1.15 Clinical Assessment of Suicidal Ideation and Behavior
Suicidal  ideati on and behavi or will  be assessed using the C-SSRS. The C- SSRS is a 3- part scale 
that measures suicidal ideat ion (eg, subject e ndorses thoughts about a wish to be dead or has other 
thoughts of suicide), intensit y of ideation (frequency , durati on, controllabilit y, deterrents, and 
reasons for ideat ion), and suicidal behavior (actually, interrupted, and aborted attempts at suicide) 
[8].
Two versions of the C -SSRS will be used in this study: TheScreening/Baseline C -SSRS Lifet ime 
and the Since -Last-Visit C-SSRS.
If the subject is unable to comply wit h the C -SSRS due to developmental status, a parent proxy  
may be used for the completion of the C -SSRS. The invest igator may also use clinical judgment to 
assess for suicidal ideat ion and behavior.
9.1.[ADDRESS_108551]
Behavior will be assessed by  [CONTACT_98639] y (ABC-C) questi onnaire, which is a rating 
scale that measures the severit y of a range of problem  behavi ors comm only observed in 
individuals wit h intellectual and developmental disabilit ies [9]. It is completed by [CONTACT_18629]. It 
is an empi[INVESTIGATOR_98610] 5 domains with 58 items: irritabilit y, agi tation, and 
TAK -935 
Study No. TAK -935-2001 Page 51of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALcrying (15 items); lethargy , soci al wi thdrawal  (16 item s); stereoty py (7 items); 
hyperact ivity/nonco mpliance (16 items); and inappropriate speech (4 items).
9.1.17 Collection of Blood Samples for PGx Evaluation
DNA form s the basis for the genes that make the body  produce proteins such as enzymes, drug 
transporters, or drug targets, and may be evaluated for the genet ic contribut ion to how the drug is 
broken down, or ho w the drug affects the body. This is called a “PGx research study.” Specific 
purposes of this study  include the following:
Identifying genet ic reasons why certain people respond differently to TAK -935.
Finding out more informat ion about how TAK -935 works.
Generat ing informat ion needed for research, development, and regulatory  approval  of tests to 
predi ct response to TAK -935.
Ident ifying variations in genes related to the bio logical target of TAK -935.
This information may be used, for example, to develop a b etter understanding of the safet y and 
efficacy  of TAK -935 and other study  drugs, to increase understanding of the disease/condit ion 
being studied, and to improve the efficiency , design, and methods of future research studies.
In the current study , collect ion of PGx blood samples is optional for each subject. A separate 
inform ed consent form  pertaining to collection, storage, and analysis of the samples must be 
signed before the PGx blood samples can be collected. The provisio n of consent to collect and 
analyze the PGx sample is independent of consent to the other aspects of the study .
One [ADDRESS_108552] ID number 
(the [ADDRESS_108553] number). Detailed instructions for the handling and 
shippi[INVESTIGATOR_98611].
A porti on of  the DNA sample will be analyzed for the presence of allelic variants in drug 
metabo lizing enzymes, drug transporters, or putative drug targets of relevance to epi[INVESTIGATOR_98612]. Addi tional PGx analyses may  be perf ormed.
The samples will be stored for no l onger than 15 years after complet ion of the TAK -935 study  
and/or until the drug development of TAK -935 is no longer actively  pursued by [CONTACT_45326]. No samples will be stored for longer than permitted by [CONTACT_45327]. “Stored samples” are defined as samples 
that are coded (the samples are stripped of all personal identifying information but a key  links the 
TAK -[ADDRESS_108554] e donor) and are used in the analysis of study 
drug or related drugs. Subjects can request that their stored samples be destroy ed at any  time.
9.1.18 PK Sample Collection and Analysis
[IP_ADDRESS] Collec tion of Plasma Samples for TAK -935 and M- I PK Evaluation
Blood sam ples (one 4 -mL sample per scheduled t ime) for the measurement of plasma 
concentrations of TAK -935 and its metabolite M -I will  be collected into chilled vacutainers 
containing the K 2EDTA acco rding to the sparse sampling schedule shown in Table 9.c. 
Table 9.c Collection of Plasma Samples for Measurement of TAK -935 and M -I in 
Plasma 
Study Part Study Day/Visit Scheduled Time
Part 1 Day 1
Days 11 and 21Before and 1, 3, 5 hours after morning dose
Before and ~1 hour after morning dose
Part 2 Day 31, 41, and 85 Before morning dose
Subjects and/or subjects’ caregivers will be instructed to not administer the morning dose of study 
drug on Day s 11, 21, 31, 41, and 85. On these days, the predose ( ie, within 30 minutes prior to 
dosing) blood sample will be co llected at the same time poin t as the bl ood sam ples f or clinical 
laboratory  tests. The m orning dose of study  drug will be administered immediately after the 
predose PK blood samples have been collected. The exact date and time of last morning and 
evening study  drug doses before each s cheduled visit, the exact time of study  drug dose taken in 
the clinic, the exact time of the last meal relative to dosing, and exact time of the PK blood draws 
will be recorded on the source document and eCRF.
For subjects who are not able to come for the visit during the morning hours, they should be 
instructed to take their morning dose, as usual, and come to the study  site during the afternoon 
hours, as feasible for the subject. While in the clinic, the site should attempt to obtain [ADDRESS_108555] ion of 
the PK sample(s).
Instructi ons for the collect ion, handling, and shippi[INVESTIGATOR_98613].
[IP_ADDRESS] Bioanalytical Methods for TAK -935 and M -I
Plasma concentrations o f TAK -935 and M -I will  be m easured by  [CONTACT_5019] -performance liqui d 
chromatography  with tandem  mass spectrom etry.
TAK-935 
Study No. TAK-935- 2001 Page 53 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL9.1.18.3 PK Parameters
The PK parameters of TAK-935 will be determined from the concentration-time profiles for all 
evaluable subjects using a population PK approach. Actual sampling times, rather than scheduled 
sampling times, will be used in all PK computations involving sampling times. 
The population PK/PD/EO model developed for TAK-[ADDRESS_108556] is found to be 
ineligible for the study at this visit, the investigator should complete the eCRF screen failure form. 
The IVRS/IWRS should be contact[CONTACT_39804] a notification of screen failure.
The primary reason for screen failure is to be r ecorded in the eCRF using the following categories:
!AE.
!Did not meet entrance criteria (specify reason).CCI
CCI
TAK -935 
Study No. TAK -935-2001 Page 55of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALSignificant protocol  deviat ion.
Lost to follow -up.
Withdrawal by [CONTACT_1130].
Study  terminated by  [CONTACT_3211].
Other (specify reason).
Subjects m ay be re-screened after consultation wit h the Medical Monitor.
Subject ID numbers assigned to subjects who fail screening should not be reused. If a subject fails 
screening, but is later successfully rescreened, the data for the subject will be entered as if the se 
were 2 separate subjects. Therefore, the data should be entered as follows:
1. The screen failure data should be entered as a screen failure subject.
2.Rescreened subjects should be assigned a new subject ID number and treated as a stand -alone 
subject.
9.1.[ADDRESS_108557] Treatment Compliance
On in -clinic dosing days, after administration of study drug orally, appropriate mouth and/or hand 
checks will be performed to ensure that the dose is swa llowed and noted in the source document. 
For those subjects receiving study  drug via G -tube/PEG -tube, the site monitor,the caregiver’s 
preparati on as provi ded in the instruction document and monitor that the caregiver has given the 
dose. If a site visit i s not possible during the morning hours, the subject should take their morning 
dose prior to attending the visit during the afternoon hours. The date and time of each dose will be 
recorded in the source documents and on the eCRFs.
Subjects and/or subjects’ caregivers will be required to bring study  drug containers/unused study  
drug and the daily recording in the dosing card to each dispensing site visit. All subjects and/or 
subjects’ caregivers shoul d be reinstructed about the dosing requirements during stu dy contacts. 
The authorized study  personnel conduct ing the re -education must document the process in the 
subject source records.
9.3 Schedule of Observations and Procedures
The schedule for all study -related procedures is shown in Appendix A. Assessments should be 
completed at the designated visit/t ime point(s).
TAK -935 
Study No. TAK -935-2001 Page 56of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL9.3.1 Screening/Baseline Period
Eligibilit y of subjects will be assessed in accordance with predefined inclusio n and exclusio n 
criteria as described in Sect ion7.0at the Screening Visit (Visit 1). See Secti on 9.1.21 for 
procedures for document ing screening failures. At the Screening Visit, subjects will be given a 
seizure diary. Subjects and/or subjects’ caregivers will be instructed to record se izure activit y on a 
daily  basis during the Screening/Baseline Period and throughout the study  after the consent has 
been signed. Diary  data can begin at the Screening Visit and record [ADDRESS_108558] on Day  1 in Part 1 (Vi sit 2).
If the subject has sat isfied all o f the inclusio n criteria an d none o f the exclusio n criteria for 
rando mizat ion, the subject should be rando mized using the IVRS/IWRS, as described in 
Secti on8.2.
9.3.[ADDRESS_108559] dose of double -blind IP (double -blind TAK -935 or placebo) 
on the m orning o f Day 1 (Vi sit 2) in the clinic after randomizat ion and after collect ion of predose 
PK, PD, AED and optional PGx blood samples. Subjects will re main in the clinic unt il complet ion 
of all study procedures on Day 1, including co llection of the PK and PD blood samples at 1, 3, and 
5 hours after the morning dose. Subjects will return to the clinic on Day 11 (Visit 3) and Day  21 
(Visit 4) f or the colle ction of blood samples for PK (before and approximately 1 hour after the 
morning dose), PD (before and approximately 1 hour after the mo rning dose), and AED (before the 
morning dose); study  drug dosing; and co llection of the seizure diary  data. For subject s who are 
not able to come for the visit during the morning hours, they  shoul d be instructed to take their 
morning dose, as usual, and co me to the study  site during the afternoon hours, as feasible for the 
subject. While in the clinic, the site should atte mpt to obtain [ADDRESS_108560] ion of the PK sample(s).
Subjects and/or subjects’ caregivers will administer the evening dose of IP to the subjects on study 
visit days and BID on all other days during the [ADDRESS_108561] and/or subject’s 
caregiver at each clinic visit.
9.3.[ADDRESS_108562] dose of study d rug (open -label TAK -935) on the mo rning of 
Day 31 (Vi sit 5) in the clinic. Subjects will remain in the clinic unt il completion of all study  
TAK -935 
Study No. TAK -935-2001 Page 57of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALprocedures during this Visit 5, including the collection of PK, PD, AED, and PGx blood samples. 
Subjects will return to the clinic on Day 41 (Visit 6) for the collect ion of PK, PD, and AED blood 
samples (all before the morning dose), study drug dosing, and co llection of the seizure diary data. 
For subjects who are not able to come for the visit during the morning hours, they should be 
instructed to take their morning dose, as usual, and come to the study  site during the afternoon 
hours, as feasible for the subject. While in the clinic, the site should attempt to obtain [ADDRESS_108563] ion of the PK sample(s).
Subjects and/or subjects’ caregivers will administer the evening dose of study drug to the subjects 
on study  visit days and BID on all other days during the approximately  60-day Open -Label 
Treatment Period. Three day s after each dose up -titrati on or de -escalat ion, subjects will be 
contact[CONTACT_98640] m onitor study  drug com pliance, conco mitant m edicat ion use, and AEs. 
Seizure di ary data will b e collected and reviewed by  [CONTACT_98641]/or 
subject’s caregiver at each clinic visit.
9.3.5 Final Visit
The Final Visit (Visit 7) is on Day  85, at which time, the appropriate dose de -escalat ion schedule 
begins (ie, if at TAK -935 300 mg B ID level, reduce to 200 mg BID for 3 days fo llowed by 100 mg 
BID for 3 days; if at the 200 mg BID level, reduce to 100 mg BID for 3 days; if at the 100 mg BID 
level, there is no de- escalat ion). PK, PD, and AED blood samples (all before the morning dose) 
will be co llected at this visit. For subjects who are not able to come for the visit during the morning 
hours, they  shoul d be instructed to take their morning dose, as usual, and co me to the study  site 
during the afternoon hours, as feasible for the subject. While in the clinic, the site should attempt to 
obtain [ADDRESS_108564] ion of the PK sample(s).
Subjects who do not enter Part 2 or wi thdraw early from the study should complete all procedures 
scheduled for the Final Visit (Visit 7) at time of withdrawal, including dose de -escalat ion as 
appropriate, followed by  [CONTACT_98642]-up Peri od (Visi ts 8 and 9).
For all subjects receiving study drug, the invest igator must complete the End -of-Study  eCRF page.
Subjects who are withdrawn early fro m the study should undergo all procedures scheduled for the 
Final Visit at the time of wit hdrawal.
9.3.6 Follow -up Phone Call
A Fo llow-up Phone Call will be cond ucted on Day 91 (Visit 8). All subjects, including those who 
withdraw early fro m the study , must com plete thi s Follow-up Phone Call.
9.3.7 Follow -up Visit
At the end of the 30- day Follow -up Peri od, subjects will return to the clinic for a Follow -up Vi sit 
on Day  121 (Visit 9). PD and AED blood samples will be co llected at this visit. All subjects, 
including those who withdraw early fro m the study, must comple te this Fo llow-up Vi sit.
TAK -[ADDRESS_108565]’s part icipation in the study. The 
subject should be returned to the care of a physician and standard therapi [INVESTIGATOR_98614]. Subjects 
may be eligible to enroll in an open -label extensio n study  expected to be init iated in 2018.
9.4 Biological Sample Retention and Destruction
In this study, specimens for genome/gene analysis will be collected as described in Section 9.1.[ADDRESS_108566] the 
subjects’ personal information to ensure optimal confidentialit y and defined standard processes for 
sample and data collect ion, storage, analysis, and destruction.
The samples will be sent to a central laboratory  that processes the blood sample and se rves as a 
secure storage facilit y. The samples will be init ially stored at [COMPANY_003] Central  Laboratory . The 
sponsor and researchers working with the sponsor will have access to the samples co llected and 
any test results. All samples collected during the study  will be stored securely wit h limited access 
and the sponsor will require anyo ne who works with the samples to agree to hold the research 
inform ation and any results in confidence.
Subjects who consented and provided PGx samples for DNA and RNA analysis can withdraw 
their consent and request disposal o f a stored sample at any time before analysis. Notify sponsor of 
consent withdrawal.
TAK -[ADDRESS_108567] who has
signed inform ed consent to participate in the study; it does not necessarily have to have a causal 
relationship with study  partici pation or treatm ent.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
labora tory value), symptom , or di sease tem porally  associ ated wi th study  parti cipat ion or use of a 
drug whether or not it is considered related to study  parti cipat ion or the drug.
10.1.[ADDRESS_108568] finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre -exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
Be considered unfavorable by [CONTACT_4168].
AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as an AE.
Diagnoses vs signs a nd symptom s:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (including 
abnorm al laboratory  values or ECG findings) or symptoms should NOT be recorded as 
additional AEs. If  a diagnosis is unknown, sign(s) or symptom(s) sho uld be recorded 
appropriately  as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory values or ECG findings are only considered to be AEs if they are judged 
to be clinically significant (ie, if so me act ion or intervent ion is required or if the invest igator 
judges the change to be beyo nd the range of normal physio logic fluctuati on). A l aboratory  or 
ECG re -test and/or continued monitoring of an abnormal value or finding is not considered an 
intervent ion. In addit ion, repeated or additional non invasive testing for verificat ion, 
evaluat ion, or m onitoring of an abnormalit y is not considered an intervention.
If abnormal laboratory values or ECG findings are the result of pathology for which there is an 
overall diagnosis (eg, increased creat inine in renal  failure), the di agnosis only  should be 
reported appropriately  as an AE.
TAK -[ADDRESS_108569] ing condit ions:
Pre-exist ing condit ions (present at the time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as AEs. Baseline evaluat ions (eg, 
laboratory  tests, ECG, X -rays) should NOT be recorded as AEs unless related to study  
procedures. However, if the subject experiences a worsening or complicat ion of such a 
concurrent medical condit ion, the worsening or complicat ion should be recorded appropriately 
as an AE (worsening or complicat ion occurs after start of study  drug). Invest igators should 
ensure that the event term recorded captures the change in the condit ion (eg, “worsening 
of…”).
If a subject has a pre -exist ing epi[INVESTIGATOR_39747] (eg, asthma, epi[INVESTIGATOR_002]) any 
occurrence of an epi[INVESTIGATOR_98615], serious, or severe in nature. Invest igators should ensure that the AE term recorded 
captur es the change in the condit ion from Baseline (eg “worsening of…”).
If a subject has a degenerat ive concurrent medical condit ion (eg, cataracts, rheumatoid 
arthri tis), worsening o f the condit ion should only be recorded as an AE if occurring to a greater 
extent to that which would be expected. Invest igators should ensure that the AE term recorded 
captures the change in the condit ion (eg, “worsening of…”).
For the purpose of this study, seizures will not be considered (S)AEs unless: 1) there is a clear 
increas e in frequency o f seizures co mpared to the subject’s baseline, 2) there is an emergence 
of a new seizure t ype, or 3) the subject experiences status epi[INVESTIGATOR_80339], and any other time the 
investigator feels the seizure should be captured as an (S)AE in which c ase the invest igator 
shoul d docum ent her/his reasoning.
Worsening of AEs:
If the subject experiences a worsening or complication of an AE after any  change in study  
drug, the worsening or complicat ion shoul d be recorded as a new AE. Invest igators should 
ensure that the AE term recorded captures the change in the condit ion (eg, “worsening of…”).
Changes in intensit y of AEs:
If the subject experiences changes in intensit y of an AE, the event should be captured once 
with the m aximum  intensity recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
inform ed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the worsening o f 
the condit ion should be recorded as an AE. Complications result ing fro m any planned surgery 
shoul d be reported as AEs.
TAK -[ADDRESS_108570] ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as AEs, but should be documented in the subject’s source documents. 
Com plicat ions result ing from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of eff icacy):
Insufficient clinical response, efficacy, or pharmacologic act ion, should NOT be recorded as 
an AE. The invest igator must make the dist inction bet ween exacerbation o f pre-exist ing illness 
and lack of therapeutic efficacy.
Overdose:
Cases of overdos e with any medication wit hout m anifested si de effects are NOT considered 
AEs, but instead will be documented in the eCRF. Any manifested side effects will be 
considered AEs and will be recorded on the AE page of the eCRF.
10.1.[ADDRESS_108571] medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were m ore severe.
3.Requi res inpat ient HOSPI[INVESTIGATOR_39749].
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDICAL EVENT that satis fies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes any event or synony m described in the [COMPANY_005] Medically  Significant AE List 
(Table 10.a).
TAK -[ADDRESS_108572]
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_39750]/ventricular fibrillation/ventricular 
tachycardiaAcute liver failure
Anaphy lactic shock
Malignant hypertension Acute renal failure
Convulsive seizure Pulmonary hypertension
Agranulocytosis Pulmonary fibrosis
Aplastic anemia Confirmed or suspected endotoxin shock
Toxic epi[INVESTIGATOR_194]/Stevens -Johnson syndrome Confirmed or suspected transmission of infectious agent by a 
medicinal product
Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
Note: Terms identified on the Medically Significant AE List represent the broad medical concepts to be considered as 
“Important Medical Events” satisfying SAE reporting requirements. 
10.1.4 Intensity of AEs
The different categories o f intensit y (severit y) are ch aracteri zed as follows:
Mild: The event is transient and easily tolerated by [CONTACT_423].
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
10.1.5 Causality of AEs
The rel ationship of each AE to study  drug will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after wi thdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments, may also be responsible.
Not Re lated: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably be explained by [CONTACT_1604], such as underlying diseases, complications, 
concomitant medications, and concurrent treatments.
10.1.6 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a stud y procedure. Otherwise, the relationship should be assessed 
as Not Related. 
TAK -[ADDRESS_108573] signs/symptoms were noted by  [CONTACT_3184]/or 
investigator.
10.1.[ADDRESS_108574] died.
10.1.9 Frequency
Epi[INVESTIGATOR_39751] c AEs (eg, vomit ing) or those which occur repeatedly over a period of consecut ive days are 
intermittent. All other events either occur once or are con tinuou s.
10.1.10 Action Concerning Study Drug
Drug Withdrawn –a study  drug i s stopped due to the particular AE.
Dose Not Changed –the parti cular AE di d not requi re stoppi [INVESTIGATOR_007] a study  drug.
Unknown –only to be used if it has not been possible to determine what action ha s been taken.
Not Applicable –a study  drug was stopped for a reason other than the particular AE, eg, the 
study  has been terminated, the subject died, or dosing with study  drug was al ready stopped 
before the onset of the AE.
Dose Reduced –the dose was re duced due to the particular AE.
Dose Interrupted –the dose was interrupted due to the particular AE.
Dose Increased –the dose was increased due to the particular AE.
10.1.11 Outcome
Recovered/Resolved –Subject returned to first assessment status with respect to the AE.
Recovering/Reso lving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
signs/symptom s has almost di sappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to Baseline; the subject died from a c ause other than the 
particular AE wi th the condi tion rem aining “recovering/resolving”.
Not Recovered/Not Resolved –there is no change in the diagnosis or signs/symptoms; the 
intensity of the di agnosis, si gns/symptoms, or laboratory  value on the last day  of the observed 
study  period has got worse than when it started; is an irreversible congenital anomaly; the 
subject died fro m another cause with the particular AE state remaining “not recovered/not 
resolved”.
TAK -935 
Study No. TAK -935-2001 Page 64of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALReso lved with Sequelae –the subject recovered f rom an acute AE but was left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal  –the AEs which are considered as the cause of death. 
Unknown –the course of the AE cannot be fo llowed up due to hospi[INVESTIGATOR_47350]’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
[IP_ADDRESS] AE Collection Period
Collect ion of AEs will co mmence fro m the time informed consent is provided at Screening
(Visit1) and continue unt il screen failure or until the Fo llow-up Visi t (Vi sit 9). For subjects who 
discontinue prior to study  drug administrati on, AEs are collected until the subject discont inues 
study  participati on.
[IP_ADDRESS] AE Reporting
At each study  visit, the investigator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study .
All subjects experiencin g AEs, whether considered associated with the use of the study  drug or 
not, m ust be m onitored until  the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to Baseline or until there is a sat isfactory  explanati on for the
changes observed. All AEs will be documented in the AE page of the eCRF, whether or not the 
investigator concludes that the event is related to the drug treatment. The fo llowing informat ion 
will be documented for each event:
1.Event term .
2.Start and stop dat e and time.
3.Frequency.
4.Intensit y.
5.Invest igator’s opi[INVESTIGATOR_3078] n of the causal relat ionship between the event and administration of study 
drug (rel ated or not rel ated).
6.Invest igator’s opi[INVESTIGATOR_3078] n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
7.Action concerning study  drug.
8.Outcom e of event.
TAK -[ADDRESS_108575] for medical evaluation should be undertaken. Through this fo llow-up, if 
it is determined that an AE not previously reported has been identified, normal reporting 
requi rements shoul d be applied (see Sect ion 10.1.2 ).
10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
An SAE should be completed in EDC with all mandatory  inform ation. If EDC is not available, a 
[COMPANY_005] SAE form must be completed, in English, and signed by [CONTACT_55740] [ADDRESS_108576] onset or notificat ion of the event. The informat ion should be completed as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject ID number.
Invest igator’s name.
Nam e of the study  drug.
Causalit y assessment.
The SAE form should be transmitted within [ADDRESS_108577] elevated >3×ULN on [ADDRESS_108578] >3×ULN and total bilirubin >2×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on
 10.2.[ADDRESS_108579] details and possible alternative etiologies, such as acute viral hepat itis A or B or 
other acute liver disease or medical history /concurrent m edical  condi tions. Fo llow
-up laboratory  
tests as described in Section 9.1.[ADDRESS_108580] be 
completed and transmitted with the [COMPANY_005] SAE form (as per Section 10.2.2 ).
TAK -[ADDRESS_108581] ion 1.1. Copi[INVESTIGATOR_014] o f any relevant data fro m the hospi [INVESTIGATOR_11533] (eg, ECGs, 
laboratory  tests, di scharge summary , postm ortem resul ts) shoul d be sent to the addressee, if 
requested.
All SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.[ADDRESS_108582] ions 
(S[LOCATION_003]Rs) and any other applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency, invest igators, and IRBs or Independent Ethics Co mmit tees (IECs), as 
applicable, in accordance with national regulat ions in the countries where the study  is conducted. 
Relative to the first awareness o f the event by /or further pr ovisio n to the sponsor or sponsor’s 
designee, S[LOCATION_003]Rs will be submitted to the regulatory  authori ties as expedited reports within 
7days for fatal and life -threatening events and 15 days for other serious events, unless otherwise 
requi red by [CONTACT_98643]. The sponsor will also prepare an expedited report for other safet y 
issues where these might materially  alter the current benefit -risk assessment of a study  
drug/sponsor supplied drug or that would be sufficient to consider changes in the study 
drug/ sponsor supplied drug administration or in the overall conduct of the study. The study site 
also will forward a copy of all expedited reports to his or her IRB or IEC in accordance with local
regul ations.
TAK -935 
Study No. TAK -935-2001 Page 67of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL11.0 STUDY- SPECIFIC COMMITTEES
No steering committee, da ta safety  monitoring commi ttee, or clinical endpoint committee will be 
used in this study . 
TAK -935 
Study No. TAK -935-2001 Page 68of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL12.0 DATA HANDLING AND RECORDKEEPI[INVESTIGATOR_85958]. 
AEs, m edical history , and concurren t medical  condi tions will be coded using the Medical 
Dictionary for Regulatory  Activities (MedDRA). Drugs will be coded using the World Health 
Organizat ion Drug Di ctionary.
12.[ADDRESS_108583] be completed in English. Data are transcribed directly  onto eCRFs.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing d ata, and questionable values. Queries may be issued by [CONTACT_1748] (or designees) and will be answered by [CONTACT_779]. 
The principal invest igator must review the eCRFs for completeness and accuracy and must e-sign
the appropriate eCRFs as indicated. Fur thermore, the invest igator must retain full responsibilit y 
for the accuracy  and authent icity of all data entered on the eCRFs .
After submissio n of the eCRFs to the sponsor, any  change of, m odificat ion of, or addit ion to the 
data on eCRFs should be made by [CONTACT_87840] o f change and modificat ion records of 
eCRFs (Data Clarificat ion Form) provided by [CONTACT_456]. The principal invest igator must review 
the Data Cl arificat ion Form  for com pleteness and accuracy , and m ust si gn and date the form .
After the l ock of  the study  database, any  change of, m odificati on of , or addi tion to the data on the 
eCRFs should be made by [CONTACT_98644] m the sponsor. The principal 
investigator [INVESTIGATOR_98616], and must si gn and date.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by [CONTACT_3552]. The sponsor or its designee will be permitted to review the subject’s 
medical and hospi[INVESTIGATOR_8735] s perti nent to the study  to ensure accuracy  of the eCRFs. The 
completed eCRFs are the sole property  of the sponsor and should not be made available in any 
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regulatory  authori ties, wi thout wri tten permissio n of the sponsor.
12.[ADDRESS_108584] igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal s ensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the aud it trail, and detailed records of drug disposit ion to 
TAK -[ADDRESS_108585]’s chart to ensure long term legibilit y. Furtherm ore, 
International Council for Harmonisation (ICH) E6 Section 4.9.[ADDRESS_108586] igator to retain 
essent ial documents specified in ICH E6 (Section 8) until at least [ADDRESS_108587] igation is discont inued and regulatory authorities 
are notified. In ad dition, ICH E6 Section 4.9.5 states that the study records should be retained unt il 
an amount of time specified by  [CONTACT_87841] a time specified in the 
study  site agreement between the investigator and sponsor.
Refer to the stu dy site agreement for the sponsor’s requirements on record retention. The 
investigator should contact [CONTACT_4182] m the sponsor before disposing of any 
such documents.
The invest igator and the head o f the study  site are requi red to reta in essent ial relevant docum ents 
until the day specified as (1) or (2) below, whichever comes later. However, if the sponsor requests 
a longer time period for retention, the head of the study  site shoul d discuss how l ong and how to 
retain those documents wi th the sponsor. 
1.The day on which market ing approval o f the study drug is obtained (or the day [ADDRESS_108588] igation is discont inued.)
2.The day  [ADDRESS_108589] igator and the head of the study  siteshoul d retain the essent ial relevant 
docum ents unt il the receipt of a sponsor -issued notificat ion to state the retention is no longer 
requi red. 
TAK-935 
Study No. TAK-935- 2001 Page 70 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A statistical analysis plan (SAP) will be prepared and finalized before database lock. This 
document will provide further details regarding the definition of analysis variables and analysis 
methodology to address all study objectives.
A blinded data review will be conducted before database lock. This review will assess the accuracy 
and completeness of the study database, sub ject evaluability, and appropri ateness of the planned 
statist ical methods.
13.1.1 Analysis Sets
The randomized set will include all subjects who were randomly assigned to treatment through the 
IVRS/IWRS.
The PK analysis set for Parts [ADDRESS_108590] 1 measurable TAK-935 or M-I plasma concentration.
The full analysis set (FAS) for Parts [ADDRESS_108591] 1 valid postbaseline value for assessment of 
the efficacy endpoint(s). In FAS efficacy summaries, subjects will be analyzed according to the 
treatment to which they were randomized. To adjust for treatment noncompliance or insufficient 
treatment exposure, one or more modified FAS populations may be defined in the SAP.
The per-protocol set (PPS) for Parts [ADDRESS_108592] 1 dose of 
study drug. In safety summaries, subjects will be analyzed according to the treatment they 
received.
13.1.2 Analysis of Demographics an d Other Baseline Characteristics
Demographic and other baseline characteristics will be summarized and listed for enrolled 
subjects by [CONTACT_6654]. Descriptive s tatistics will be used  to summarize data for 
continuous variables such as age and weight (eg, number of subjects, mean, median, SD, and 
range) and for categorical variables such as sex, ethnicity, and race (number and percentage of 
subjects within each category). Medical history and medication history will be listed by [CONTACT_1130].CCI
TAK-935 
Study No. TAK-935- 2001 Page 71 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIAL13.1.3 Safety Analysis
[IP_ADDRESS] AEs
AEs will be reported throughout the study. TEAEs will be a primary endpoint for each part of the 
study. TEAEs will be summarized using descriptive statistics (number and percentage of subjects) 
for the safety analysis set. No statistical testing will be performed or inferential statistics will be 
generated.
The definition of TEAEs will be provided in the SAP. AEs will be coded using MedDRA and will 
be summarized by [CONTACT_98645].
AEs that were reported more than once by a subject during a part of the study will be counted only 
once for that subject at the maximum severity.
[IP_ADDRESS] Other Safety Endpoints
Absolute values and changes from Screening/Baseline for clinical laboratory tests, vital signs, and 
ECGs will be summarized by [CONTACT_98646]. 
Clinical laboratory test, vital sign,  and ECG results that are outside the normal 
ranges and potentially clinically significant will be flagged and tabulated. The number and 
percentage of subjects with clinical laboratory tes t, vital sign, weight/BMI, and ECG parameter 
values that meet [COMPANY_005]’s predefined criteria for markedly abnormal values at least once postdose 
will be summarized by [CONTACT_98624]. Physical examination findings will be listed 
by [CONTACT_98647].
13.1.[ADDRESS_108593] 
and summarized by [CONTACT_98625].
A population PK/PD analysis approach will be used to determine the population estimates for 
TAK-935. The PK and PD parameters for TAK-935 will be summarized in a separate population 
PK/PD report.
13.1.5 Secondary and Exp loratory Analyses
Safety (clinical laboratory evaluations, vital signs, weight/BMI, and ECGs) and PK (TAK-935) 
endpoints will be analy zed as the secondary endpoints in the study.  
 CCI
CCICCICCI
TAK-[ADDRESS_108594] discontinued from 
the study (and prior to completion of the Open -Label Period), an unblinded safety summary may 
be generated. There will be no early stoppi[INVESTIGATOR_98617].
13.3 Determination of Sample Size
Approximately 20 adult subjects are planned to be randomized. A formal sample size calculation 
was not performed for this study. The current sample size is deemed appropriate to evaluate the 
safety and tolerability of TAK-935 before dosing in pediatric subjects <[ADDRESS_108595] igator and the study site guarantee access to sourc e documents by  [CONTACT_3210] i ts 
designee (contract research organization) and by [CONTACT_1201].
All aspects of the study and its documentation will be subject to review by [CONTACT_4209]’s 
designee (as long as blinding is not jeopardized), including bu t not limi ted to the Investi gator’s 
Binder, study  drug, subject m edical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and review o f eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are available during the mo nitoring visits and that sufficient time is 
devoted to the process.
14.[ADDRESS_108596] to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee ( and IRB, as required) to determine the appropriate course of action. There will be no 
exempt ions (a prospectively  approved deviat ion) from the inclusio n or excl usion cri teria.
The site should document all protocol deviat ions in the subject’s source documen ts. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB, as required). 
Significant deviat ions include, but are not limited to, those that invo lve fraud or misconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. A 
Protocol  Deviat ion Form should be completed by [CONTACT_98648] .
Every  attem pt will be m ade to collect each PK and PD b lood sam ple at the desi gnated time point, 
and the actual time of each blood sample will be recorded on the source document and eCRF. 
Table 14.adefines the target windows for sample collect ions. Samples collected outside of these 
collect ion windows will not be considered a protocol deviation after Day  [ADDRESS_108597] be collected prior to dosing on Day  1.
TAK -935 
Study No. TAK -935-2001 Page 74of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALTable 14.a Windows for PK and PD Blood Sample Col lection
Study Part and Day Nominal/Target Sampling Time Window
Part 1, Day 1 Predose (0 hour) No more than 30 minutes predose
Part 1, Day 1 1, 3 and 5 hours postdose ±15 minutes of nominal time
Part 1, Days 11 and 21 Predose and 1 hour postdose No more than 30 minutes predose, 
and ±15 minutes of nominal time, 
respectively
Part 2, Days 31, 41, and 85 Predose No more than 30 minutes predose
Part 1, Day 1 Predose (0 hour) No more than [ADDRESS_108598] the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the fac ilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by [CONTACT_17513], including 
those of for eign governments (eg, the Food and Drug Administration [FDA], the United Kingdo m 
Medicines and Healt hcare products Regulatory Agency, the Pharmaceut icals and Medical Devices 
Agency o f Japan). If the study site is contact[CONTACT_4190] a regulatory body , the sponsor 
shoul d be notified immediately. The invest igator and study site guarantee access for qualit y 
assurance auditors to all study  docum ents as described in Sect ion 14.1.
TAK -[ADDRESS_108599] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GC P. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilit
ies.
15.[ADDRESS_108600] concerns should instead provide a Federal Wide Assurance Number or comparable 
number assigned by  [CONTACT_98649] h and Human Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB for 
the protocol’s review and approval. This protocol , the Invest igator’s Brochure, a copy of the 
inform ed consent form, and, if applicable, subject recruit ment materials and/or advertisements and 
other documents required by [CONTACT_39823], must be submitted to a central or 
localIRB for approval. The IRB’s written approval o f the protocol  and subject informed consent 
must be obtained and submitted to the sponsor or designee before commencement of the study  
(ie,before shipment of the sponsor -supplied drug or study specific screen ing act ivity). The IRB 
approval  must refer to the study by [CONTACT_1764], number, and versio n date; ident ify versio ns 
of other documents (eg, informed consent form) reviewed; and state the approval date. The 
sponsor will notify  the si te once the spo nsor has confirmed the adequacy of site regulatory  
docum entati on and, when applicable, the sponsor has received permissio n from competent 
authori ty to begin the study .
Study  sites m ust adhere to all requirements st ipulated by [CONTACT_87850]. This may include 
notification to the IRB regarding protocol amendments, updates to the informed consent form, 
recrui tment m aterials intended for viewing by  [CONTACT_1766], l ocal safet y reporti ng requirements, 
reports and updates regarding the ongoing review of the study at intervals specified by  [CONTACT_87851], and submissio n of the investigator’s final status report to IRB. All IRB approvals 
and relevant documentation for these items must be provided to the sponsor or its designee.
Subject incentives should not exer t undue influence for participat ion. Payments to subjects must 
be approved by [CONTACT_87852].
TAK -[ADDRESS_108601] authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the plan ned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of thestudy , its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB approval o f the inform ed 
consent form and if applicable, the subject authorization form. The informed consent form, subje ct 
authori zation form (if applicable), and subject info rmation sheet (if applicable) must be approved 
by [CONTACT_98650].
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if app licable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject info rmation sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by  [CONTACT_1201]. In the event the subject is not capable of rendering 
adequate written informed consen t, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) in quire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject a uthorizat ion form (if applicable) m ust be 
signed and dated by  [CONTACT_423], or the subject’s legally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
acceptable represen tative shoul d be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  [CONTACT_1289].
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject infor mation sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copi[INVESTIGATOR_1681], the signed subject auth orization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
TAK -[ADDRESS_108602]’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
Subjects who consented and provided a PGx sample for DNA (and RNA) analysis can wit hdraw 
their consent and request disposal o f a stored sample at any  time pri or to analysis. Notify  sponsor 
of consent wi thdrawal.
15.[ADDRESS_108603]’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical trial database or documentation via a subject ID number. As permitted by [CONTACT_98651], limited subject attributes, such as sex, age or date of birth, and 
subject init ials may be used to verify the subject and accuracy  of the subject’s unique ID number.
To com ply with ICH Guidelines for GCP a nd to verify co mpliance with this protocol, the sponsor 
requi res the invest igator to permit the monitor or the sponsor’s designee, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical  Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs to review the subject’s original medical records (source data or documents), 
including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n and discharge 
summaries for hospi[INVESTIGATOR_1684] a subject’s study  parti cipat ion, and autopsy  
reports. Access to a subject’s original medical records requires the specific authorization o f the 
subject as part of the informed consent process (se e Secti on 15.2).
Copi [INVESTIGATOR_39757] (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.[ADDRESS_108604] igators or to regulatory  agencies, except as required by  
[CONTACT_6617]. Except as o therwise allo wable in the study site agreement, any public disclosure 
(including publicly accessible websites) related to the protocol or study  resul ts other than study  
recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  [CONTACT_3170]) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropriately reflect cont ribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
TAK -[ADDRESS_108605] ion and the study site agreement. In the event of any discrepancy between the protocol and 
the study  site agreement, the study  site agreement will  prevail.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions, and guidance, [COMPANY_005] will, at a minimum register a ll 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in [COMPANY_005] Policy/Standard . [COMPANY_005] 
contact [CONTACT_4203], along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist callers in lo cating study  sites cl osest to thei r homes by 
[CONTACT_39824], address , and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact [CONTACT_4203], they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries accord ing to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor. Any 
investigator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site.
15.4.[ADDRESS_108606] the results of clinical trial son ClinicalTrials.gov and/or other publicly accessible 
websit es, as requi red by [CONTACT_39825]/Standard, applicable laws and/or regulat ions.
15.[ADDRESS_108607] is participat ing. If a local underwri ter is requi red, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensat ion and treatmen t for 
injury . If the invest igator has questions regarding this policy, he or she should contact [CONTACT_39826]’s designee.
TAK -935 
Study No. TAK -935-2001 Page 79of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIAL16.0 REFERENCES
1.Paul SM, Doherty  JJ, Robi chaud AJ, Belfort GM, Chow BY, Hammond RS, et al. The major 
brain cho lesterol  metabo lite 24(S) -hydroxycho lesterol  is a potent allo steric modulator of 
N-methyl-D- aspartate receptors. J Neurosci 2013;33(44):[ZIP_CODE] -300.
2.Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised 
termino logy and concepts for organ ization of seizures and epi[INVESTIGATOR_31629]: report of the ILAE 
Commissio n on Classificat ion and Termino logy, 2005 -2009. Epi[INVESTIGATOR_8330] 2010;51(4):676 -85.
3.Scheffer IE, Berkovic S, Capovilla G, Conno lly MB, French J, Guilhoto L, et al. ILAE 
classificat ion of the epi[INVESTIGATOR_98618]: Posi tion paper of the ILAE Commission for Classificat ion and 
Termino logy. Epi[INVESTIGATOR_8330] 2017;58(4):[ADDRESS_108608] the balance between c erebral  producti on and hepat ic 
metabo lism and are inversely related to body  surface. J Li pid Res 2000;41(5):840-5.
5.Cartagena CM, Ahmed F, Burns MP, Pajoohesh -Ganji  A, Pak DT, Faden AI, et al. Cortical 
injury  increases chol esterol  24S hydroxylase (Cyp46) levels in the rat brain. J Neurotrauma 
2008;25(9):1087 -98.
6.Tian G, Kong Q, Lai L, Ray -Chaudhury  A, Lin CG. Increased expressio n of cho lesterol 
24S- hydroxylase results in disruption o f glial glutamate transporter EAAT2 associat ion with 
lipid rafts: a po tential role in Alzheimer's disease. J Neurochem 2010;113(4):[ADDRESS_108609] Epi[INVESTIGATOR_002]: Posit ion Paper of 
theILAE Commissio n for Classificat ion and Termino logy. Epi[INVESTIGATOR_8330] 2017.
8.Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicide Severit y Rat ing Scale: init ial validit y and internal consistency findings fro m 
three m ultisite studi es wi th adol escents and adults. Am J Psychiatry  2011;168(12):1266-77.
9.Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior 
rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89(5):485 -91.
TAK -935 
Study No. TAK -935-2001 Page 80of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALAppendix ASchedule of Study Procedures 
Screening/
Baseline Period (a)Part 1: Double -Blind
Treatment Period (b)Part 2: Open- Label
Treatment Period (b) Follow -up Period (c)
Study Day Days -41 to 0 Day 1 Day 11 Day 21 Day 31 Day 41 Day 85 (c,d) Day 91 Day 121
Visit Window (days) ±2 ±2 ±2 ±2 ±2 ±2 ±2
Visit Number 1
Screening 
Visit2 3 4 5 6 7
Final 
Visit8
Follow -up 
Phone Call9
Follow -up 
Visit
Informed consent and assent, if 
appropriateX
Optional PGx informed consent X
Inclusion/exclusion criteria X X
Randomization X
Demographics, medical history, 
medication historyX
Height, weight, BMI X
Concurrent medical conditions X
Concomitant medications, including 
AED X X X X X X X X X
Urine drug and alcohol screen (e) X
HIV, HBsAg, HCV tests (f) X
C-SSRS, if appropriate (g) X X X
Aberrant behavior checklist X X X X X X X
FSH and estradiol (h) X X
Serum/urine pregnancy test (i) X(serum) X(urine) X(serum)
Pregnancy avoidance counseling X X X X X X X X
Vital signs X X X X X X X X
Physical examination (j) X X X
(Footnotes follow table.)
TAK-935 
Study No. TAK-935-2001 Page 81 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIALAppendix A Schedule of Study Procedures (continued)
Screening/
Baseline Period (a)Part 1: Double-Blind
Treatment Period (b)Part 2: Open-Label
Treatment Period (b) Follow-up Period (c)
Study Day Days -41 to 0 Day 1 Day 11 Day 21 Day 31 Day 41 Day 85 (c,d) Day 91 Day 121
Visit Window (days) ±2 ±2 ±2 ±2 ±2 ±2 ±2
Visit Number 1
Screening 
Visit2 3456 7
Final 
Visit8
Follow-up 
Phone Call9
Follow-up 
Visit
Neurological exam, including 
fundoscopy and visual acuity (if 
possible) (k)XX X
12-lead ECG X X X X
Clinical laboratory tests (l) X X X X
Plasma sample for TAK-935 PK (m,n) X X X X X X
Plasma sample for AED analysis (n,o) X X X X X X X
Plasma sample for PD (n,p) X X X X X X X X
Blood sample for DNA PGx (q) X
Blood sample for RNA PGx (n,r) X X
Access IVRS/IWRS for subject 
ID/medication ID/subject status (s)X X XXXX X
Assess benefit-risk analysis with subject 
and caregiver before increasing dose to 
[ADDRESS_108610] (t) X X X X X X
In-clinic administration of morning dose 
of study drug (u)X XXXX X
(Footnotes follow table.)CCI
CCI
TAK -935 
Study No. TAK -935-2001 Page 82of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALAppendix A Schedule of Study Procedures (continued)
Screening/
Baseline Period (a)Part 1: Double -Blind
Treatment Period (b)Part 2: Open- Label
Treatment Period (b) Follow -up Period (c)
Study Day Days -41 to 0 Day 1 Day 11 Day 21 Day 31 Day 41 Day 85 (c,d) Day 91 Day 121
Visit Window (days) ±2 ±2 ±2 ±2 ±2 ±2 ±2
Visit Number 1
Screening 
Visit2 3 4 5 6 7
Final 
Visit8
Follow -up 
Phone Call9
Follow -up 
Visit
Study  drug return/
accountability/complianceX X X X X X
Assess AEs (v) X X X X X X X X X
Footnotes for Appendix A
(a) The 4 -week baseline seizure diary recording can begin as soon as the ICF has been signed. Randomization can occur once the 4 -week baseline seizure count of ≥[ADDRESS_108611] meets all of the inclusion and none of the exclusion crite ria.
(b) Three days after each dose up -titration or de -escalation, subjects will be contact[CONTACT_98622], concomitant medication use, and AEs.
(c) Subjects who do not enter Part [ADDRESS_108612] ete all procedures scheduled for the Final Visit (Visit 7) at time of withdrawal, including dose 
de-escalation as appropriate, followed by [CONTACT_98652] -up Period (Visits 8 and 9). See Section 6.1for details.
(d) Dose de -escalation, as appropriate, begins at the Final Visit (ie, if at TAK -935 300 mg BID level, reduce to 200 mg BID for 3 days followed by 100 mg BID for 3 days; if at the 
200mg BID level , reduce to 100 mg BID for 3 days; if at the 100 mg BID level, there is no de -escalation). See Section 6.1for details.
(e) If urine cannot be collected, the reason should be documented in the source document.
(f) Subjects who are positive for hepatitis C Ab should return to the clinic for an unscheduled visit to provide a blood samp le for HCV qPCR
(g) If the subject is unable to comply with the C-SSRS due to developmental status, a parent proxy may be used for the completion of the C -SSRS. The investigator may also use 
clinical judgment to assess for suicidal ideation and behavior.
(h) For female subjects only at the Screening and Final Visits.
(i) For female subjects of childbearing potential, a serum pregnancy (hCG) test will be performed at the Screening and Final V isits and a urine pregnancy test will be performed before 
the morning dose on Day 1 in Part 1 (Visit 2). If urine cannot be collect ed, the reason should be documented in the source document and the serum pregnancy test obtained at Visit [ADDRESS_108613] be confirmed to be negative by [CONTACT_98653]. Additional pregnancy tests may be performed thro ughout the study at the investigator’s discretion.
(j) PE must be captured in the source document. Any clinically significant abnormalities noted prior to administration of stu dy drug should be described and captured on the Medical 
History form. Any clinically significant change s in PE noted after administration of study drug should be captured on the AE page of the eCRF.
(k) Any clinically significant abnormalities noted prior to administration of study drug should be described and recorded on the Medical History form. Any clini cally significant 
changes in the neurological examination noted after administration of study drug should be captured on the AE page of the eCR F.
(l) Hematology, serum chemistry, and urinalysis tests. If urine cannot be collected due to the subject’s coope ration or because the subject is wearing a diaper, it is acceptable for the 
subject to continue in the study and the reason should be documented in the source document.
(m) PK plasma samples for measurement of TAK -[ADDRESS_108614] ed before and 1, 3, and 5 hours after the morning dose on Day 1; before and 
approximately 1 hour after the morning dose on Days 11 and 21; and before the morning dose on Days 31, 41, and 85.
(n) On Days 11, 21, 31, 41, and 85, subjects should visit the cli nic in the morning prior to taking their morning dose. For subjects who are not able to come for the visit during the 
TAK-[ADDRESS_108615] be recorded in the eCRF upon collection of the 
PK sample(s).(o) Plasma samples for measurement of concomitant AED concentrations will be collected before the morning dose on Days 1, 11, 2 1, 31, 41, and 85; and at the Follow-up Visit 
(Day 121).
 
(q) One PGx blood sample for DNA isolation will be collected before the morning dose on Day 1.
(r) Two PGx blood samples for RNA isolation will be collected before the morning dose on Days 1 and 31.(s) The dose of IP will be increased on Days 11 and 21 in Part 1 and on Day 41 in Part 2, provided there are no safety or toler ability concerns. Subjects’ dose may be increased or 
decreased before Day 41 (Visit 6) based on clinical condition (ie, in creasing seizures) and investigator judgment. At the end of  Part 2, the dose of TAK-935 will be de-escalated before 
dosing is discontinued. See Section  6.1for details.
(t) A dosing card will be provided to record daily AM and PM study drug administration throughout the study, including changes in dosing regimen (de-escalation) that may occur 
between visits and during the de-escalation period of the study.
(u) On in-clinic dosing days, after administration of study drug, appropriate mouth and/or hand checks will be performed to ensu re that the dose is swallowed and noted in the source 
document. If a site visit is not possible during the morning hours, the subject should take their morning dose prior to attendi ng the visit during the afternoon hours. The date and time 
of each dose will be recorded in the source documents and on the eCRFs.(v) Collection of AEs will commence from the time informed consent is provided (Screening Visit) and continue until screen fail ure or the Follow-up Visit.CCI
TAK -[ADDRESS_108616] igators by  [CONTACT_45348] “Statement of Invest igator” (Form FDA 1572), whi ch must be com pleted and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by [CONTACT_2960] a Form  FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assist in the protocol.
3.If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and should implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions perfo rmed and any 
data generated. 
4.Ensure that study -related procedures, including study -specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodi es/authori ties.
5.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
6.Secure prior approval o f the study and any changes by [CONTACT_4215]/IEC that conform to 
21 Code of Federal Regulations (C FR) Part 56, ICH, and local regulatory  requi rements.
7.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within [ADDRESS_108617]’s medical chart. Valid informed consent is the most current 
versio n approved by [CONTACT_1201]/IEC. Each informed consent form s hould contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not includ e such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospi[INVESTIGATOR_1097], laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by [CONTACT_98654] -[ADDRESS_108618]:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the resea rch.
3.The expected duration of the subject’s participat ion.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject m ay receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A statement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regul atory  agencies, auditor(s), IRB/IEC, 
and the monitor may inspe ct the records. By  [CONTACT_2960] a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  consist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The a nticipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to contact [CONTACT_39831] 
(invest igator), subject’s rights, and IRB/IEC and who m to contact i n the event of a 
research -related inj ury to the subject.
TAK -[ADDRESS_108619]’s 
legally acceptable repres entative may  discontinue parti cipat ion at any  time wi thout penal ty or 
loss of benefit s to whi ch the subject is otherwise ent itled.
20.The consequences of a subject’s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by [CONTACT_423].
21.A statement that the subject or the subject’s legally acceptable representative will be informed 
in a timely  manner if informat ion beco mes available that may be relevant to the subject’s 
willingness to continue participat ion in the study .
22.A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal information (including personal healt h informat ion) may be processed by  [CONTACT_45351] y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assist ing [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs/IECs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, [COMPANY_005] will make every  effort to keep y our personal  information confident ial, 
and y our name [CONTACT_39846] [CONTACT_2371];
c)that personal information (including personal healt h informat ion) may be added to 
[COMPANY_005]’s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safet y and effect iveness o f the study  drug(s), stud ying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclo sure of their personal informat ion 
(including personal healt h information) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
TAK -935 
Study No. TAK -935-2001 Page 88of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALe)that the subject’s ident ity will remain confident ial in the event that study  resul ts are 
published.
25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use highly  effect ive contraception (as defined in the informed 
consent) from Screening throughout the duration of the s tudy, and for [ADDRESS_108620] ive contraceptio n (as defined in the informed consent) 
from signing the informed consent throughout the duration of the study , and for [ADDRESS_108621] igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
[LOCATION_008], [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assist ing [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may beretained, processed, and transferred by [CONTACT_39833]:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  drug.
Inspect ions and invest igations by [CONTACT_4218].
Self-inspect ion and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact [CONTACT_4203], study det ails, and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data pro tection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by [CONTACT_47407].
TAK -[ADDRESS_108622] ion(s) of the protocol affected by [CONTACT_39835]. 03 are indicated. 
The corresponding text has been revised throughout the protocol.
Change 1: Clarified that TAK -[ADDRESS_108623] acebo can be administered either orally or via stable 
G-tube/ PEG tube.
The primary  change occurs in Sect ion 6.1Study  Design
Added text: or via gastrostomy tube (G -tube)/ percutaneous endoscopic gastrostomy (PEG) 
tube
Rationale for Change: To allow administration of TAK -[ADDRESS_108624] acebo via G -tube/PEG tube 
after finalizat ion of CMC in vitro studies demo nstrating nearly 100% drug delivery through a 
G-tube when crushed and suspended in water.
The fo llowing sect ions also contain this change:
Section 2.0STUDY SUMMARY
Secti on 4.1Background
Secti on 6.1Study  Design
Secti on 6.2Justificat ion for Study  Design, Dose, and Endpo ints
Secti on 8.1.3 Dose and Regimen
Secti on 9.2Moni toring Subject Treatment Compliance
Change 2: Clarified that a separate consent form will be obtained for subje cts wi th G-tube/PEG 
tubes.
The primary  change occurs in Secti on 9.1.1 Informed Consent Procedure
Added text :In addition, a separate supplemental informed consent form ( ICF)providing 
information on G -tube/PEG -tube administration of study drug will be signed.
Rationale for Change: To provide detail on separate consent form for subjects with G -tube/PEG 
tubes.
TAK -[ADDRESS_108625] ions also contain this change:
Secti on 7.1Inclusion Criteria
Change 3: Added inclusio n criteria rel ated to subjects with G -tube/PEG tubes.
The primary  change occurs in Secti on 7.1 Inclusio n Cri teria
Added text :For subjects with G -tube/PEG tube, G -tubes/PEG tubes should have been placed 
and been functioning for at least 3 months prior to screening. Naso -gastric tubes 
are not allowed.
Rationale for Change: To clarify the subject populat ion with G-tube/PEG tubes.
The fo llowing sect ions also contain this change:
Secti on 7.4Diet, Fluid, and Act ivity Control
Change 4: Modified exclusio n criteria to all ow the use of m edical marijuana.
The primary  chan ge occurs in Secti on 7.2Exclusio n Cri teria
Initial 
wording:The subject has a history  of alcohol , opi[INVESTIGATOR_2480], or othe r drug use disorder, as per the 
Diagnostic and Stati stical Manual of Mental Disorders, Fift h Edit ion, wi thin the 
previous 2 years before Screening (Visit 1). Previous sporadic cannabis use is not 
exclusio nary provi ded the subject is requested and agrees to not use cannabis during 
the study .
Amended 
or new 
wording:The subject has a history  of alcohol , opi[INVESTIGATOR_2480], or othe r drug use disorder, as per the 
Diagnostic and Stati stical Manual of Mental Disorders, Fift h Edit ion,within the 
previous 2 years before Screening (Visit 1). Previous sporadic cannabis use is not 
exclusio nary provi ded the subject i s requested and agrees to not use cannabis during 
the study .Medical marijuana use is allowed.
Rationale for Change: To allow enrollment of subjects in states where use of medical marijuana 
is legal.
The fo llowing sect ions also contain this change:
Secti on 7.3Excluded Medications, Procedures, and Treatments
TAK -935 
Study No. TAK -935-2001 Page 92of 93
Protocol Incorporating Amendment No. 03 21March 2018
CONFIDENTIALChange 5: Modified secondary endpo ints to rem ove est imation of addit ional parameters.
The primary  change occurs in Secti on 5.2.2 Secondary Endpo ints
Deleted 
text:Popul ation mean estimates of drug clearance (CL), volume o f distribut ion of the 
central  com partment (V c), absorption rate constant (K a), vol ume of di stribut ion of 
the peripheral co mpartment (V p), intercompartmental clearance (Q), the 
maximum plasma concentration (C max), the area under the plasma 
concentration -time curve over a dosing interval (AUC 0-tau), the average 
concentration during a dosing interval at steady -state (C av,ss), and the pl asma 
concentration immediately prior to dosing (C trough) for TAK -935. Addit ional 
param eters m ay be estimated, if appropriate.
Rationale for Change: To keep endpoints specific and consistent guidelines for disclosure of 
study  details.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Change 6: Removed body weight/body  mass index (BMI) fro m secondary and exploratory  
endpo ints.
The primary  change occurs in Secti on 5.2.2 Secondary Endpo ints
Deleted 
text:Percentage of subjects with at least 1 markedly abnormal value for clinical 
laboratory  evaluat ions, vital signs, body  weight/body  mass index (BMI), and 
electrocardi ogram  (ECG) param eters after TAK -935 treatm ent.
Rationale for Change: These parameters are only measured at screening and therefore change 
cannot be monitored.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Secti on 5.2.3 Exploratory  Endpo ints
Change 7: Modified study drug dosing and regimen sect ions to cl arify how study  drug will be 
administered via G -tube/ PEG tube.
The primary  change occurs in Secti on 8.1.1 Dosage Form, Manufacturing, Packaging, and 
Labeling
Added text: For subjects receiving study drug via G -tube/PEG tube, tablets will be crushed, 
suspended in water, and the suspension will be administered via the G -tube/PEG 
tube using a syringe. Complete instructions will be provided to 
subjects/caregivers in a document provided outside of the protocol.
TAK-935 
Study No. TAK-935- 2001 Page 93 of 93
Protocol Incorporating Amendment No. 03 21 March 2018
CONFIDENTIALRationale for Change: To provide clarification on study dosing and regimen for subjects with 
G-tube/PEG tubes.
The following sections also contain this change:
!Section  8.1.3 Dose and Regimen
Change  8: Modified study drug dispensing procedures to clarify how the investigative product 
(IP) will be prepared for administration via G-tube/PEG tube.
The primary change occurs in
Added text: In addition to the above, subjects/caregivers will be provided complete 
instructions on preparing the study drug for administration via 
G-tube/PEG-tube in a document provided outside of the protocol. They should 
follow these instructions carefully.
Rationale for Change: To provide clarification on study dosing and regimen for subjects with 
G-tube/PEG tubes.
Change  9: Clarified when open-label extension study is expected to be initiated.
The primary change occurs in Section  9.3.8 Poststudy Care
Initial 
wording:Study drug will not be available upon completion of the subject’s participation in the 
study. The subject should be returned to the care of a physician and standard therapi[INVESTIGATOR_98619]. Subjects may be eligible to enroll in an open-label extension study if and 
when available.
Amended or new 
wording:Study drug will not be available upon completion of the subject’s participation in the 
study. The subject should be returned to the care of a physician and standard therapi[INVESTIGATOR_98619]. Subjects may be eligible to enroll in an open-label extension study if and 
when available expected to be initiated in 2018 .
Rationale for Change: To provide information to sites/subjects as to when the open-label 
extension study will be initiated.
Change  10: Updated the medical monitor contact [CONTACT_3031].
The primary change occurs in Section  1.1 Contacts
Description 
of change:The contact [CONTACT_98655]  
.
Rationale for Change: Due to a change in medical monitor at the Clinical Research Organization.[COMPANY_003]
 䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by [CONTACT_4232] 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   



GHIH䣖䣃䣍䢯䢻䢵䢷䢯䢴䢲䢲䢳䢯䣒䣴䣱䣶䣱䣥䣱䣮䢯䣃䣯䣧䣰䣦䢯䢲䢵
&OLQLFDO$SSURYDO 0DU87&
&OLQLFDO$SSURYDO 0DU87&
%LRVWDWLVWLFV$SSURYDO 0DU87&[COMPANY_003]